{
  "$schema_version": "5.4",
  "review_mode": "revision",
  "schema_extensions": {
    "id": "local-reference-edition-2",
    "base_schema_version": "5.2",
    "base_validator_version": "2.2",
    "added_subclaim_types": [
      "reversibility",
      "prevention"
    ],
    "scope_alias": "scope equals canonical claimed_scope and is checked.",
    "prevention_definition": "Exposure control before the adverse developmental outcome; not reversal after it.",
    "endpoint_accounting": "Five evidence rows, three qualifying causal modalities, one direct human developmental-prevention modality. Not five independent ID trials.",
    "rubric_adaptation": "Universal ladder plus explicit inherited-developmental-metabolic interpretation; aging endpoints are not applied literally.",
    "pass_02_note": "Migrated to schema 5.4 in red-team pass-02 (lay_summary; ledger pmid/doi/url on every row; claims register consistent with gate_passed). Local 'prevention' type retained."
  },
  "claim_restatement": {
    "index_wording": "Phenylalanine accumulation from PAH deficiency causes intellectual disability, preventable by dietary restriction",
    "entry_form": "conjunction",
    "gradeable_restatement": "Sustained marked phenylalanine elevation caused by PAH-deficient phenylketonuria is a major cause of developmental intellectual disability, which can be prevented by early, sustained, nutritionally adequate dietary phenylalanine restriction.",
    "restatement_required": true,
    "split_into": [
      "SC1",
      "SC2",
      "SC3"
    ],
    "parent_claim": null,
    "scope_clarification": "Timing, degree/duration of biochemical exposure and nutritional adequacy are substantive clarifications, not hidden universal guarantees. Mild elevations, protected untreated patients and incomplete prevention remain reported. No eligibility depends on subsequent cognition or response.",
    "scope_qualifiers": [
      {
        "qualifier": "PAH-deficient phenylketonuria",
        "determinable_before_outcome": true,
        "determined_from": "diagnostic biochemical severity and PAH genotype at newborn screening; never from later cognition or dietary response",
        "action": "retained"
      },
      {
        "qualifier": "developmental exposure",
        "determinable_before_outcome": true,
        "determined_from": "age at initiation of restriction and documented exposure window",
        "action": "retained"
      },
      {
        "qualifier": "begun early and sustained with nutritional adequacy",
        "determinable_before_outcome": true,
        "determined_from": "treatment start date and prospectively recorded phenylalanine control, both fixed before outcome assessment",
        "action": "retained"
      },
      {
        "qualifier": "in susceptible individuals",
        "determinable_before_outcome": false,
        "determined_from": "not defined independently of who developed impairment",
        "action": "deleted"
      }
    ],
    "_scope_note": "The fourth qualifier was never present in either input grading; it is recorded here as a deleted candidate because it is the form that failed in the H. pylori review, and both PKU protocols explicitly guarded against it. Neither future impairment nor dietary response may define an eligible group."
  },
  "lay_summary": {
    "paragraphs": [
      "Phenylketonuria (PKU) is an inherited condition in which the liver lacks a working enzyme that normally breaks down phenylalanine, one of the building blocks of dietary protein. Without that enzyme, phenylalanine builds up in the blood. The claim reviewed here is that this build-up is what causes the severe intellectual disability seen in people with PKU who are never treated, and that a diet low in phenylalanine, started in the first weeks of life and kept up through childhood, prevents it.",
      "This review grades the claim Θ (theta), the second-highest level on its scale: the explanation predicts what happens with high accuracy and leaves only a few exceptions unexplained. The strongest evidence comes from comparisons that history made possible. Affected brothers and sisters treated early developed far better than those treated late or not at all. Children did worse the later treatment started and the less tightly phenylalanine was controlled. Babies without PKU, carried by mothers with PKU and high phenylalanine, were harmed in step with the mother's levels. A rare minority of untreated people escape intellectual disability; why they are protected is still unknown, although many of them still show other signs of harm.",
      "Explaining and predicting that protection in advance would move the grade toward the top of the scale; finding that it reflects something unrelated to phenylalanine would lower it. The grade describes the strength of the evidence that phenylalanine is the cause. It is not a judgement of anyone's care, and this summary gives no advice about diet or treatment. The previous edition graded the claim one level lower; the change and its reasons are recorded openly below."
    ],
    "grade_restated_faithfully": true,
    "claims_referenced": [
      "C3",
      "C4",
      "C5",
      "C20",
      "C22",
      "C24",
      "C26",
      "C27",
      "C33",
      "C34"
    ],
    "jargon_glossed": [
      "phenylketonuria (PKU)",
      "phenylalanine",
      "enzyme",
      "Θ (theta)"
    ],
    "no_practical_advice": true,
    "written_for": "general reader, no field background",
    "placement_note": "Placed before the AT A GLANCE block in the prose, per hsef-framework.md ('placed before any technical content'); the v5.4 review template places it after the provenance header — flagged as a template inconsistency."
  },
  "hypothesis": {
    "name": "PAH deficiency, phenylalanine accumulation and preventable developmental intellectual disability",
    "central_claim": "Sustained marked phenylalanine elevation caused by PAH-deficient phenylketonuria is a major cause of developmental intellectual disability, which can be prevented by early, sustained, nutritionally adequate dietary phenylalanine restriction.",
    "proposed_mechanism": "Reduced PAH conversion of Phe to tyrosine produces excess Phe exposure. Brain amino-acid handling, protein/neurotransmitter biology and other downstream processes mediate developmental injury; no single molecular route is claimed to be completely established.",
    "claimed_scope": "disease-class",
    "claimed_level": [
      "initiation",
      "progression",
      "response"
    ],
    "is_conjunctive": true,
    "conjunctive_note": "The user asserts the metabolic link, causal disability and dietary prevention jointly; all are required for the overall assessment."
  },
  "rubric_routing": {
    "primary_rubric": "universal hsef-framework.md",
    "secondary_rubrics": [
      "06-metabolism-aging.md (read for fit, not applied literally)"
    ],
    "index_notes_applied": [
      "No PAH/PKU entry was identified."
    ],
    "rubric_fit_note": "Rubric 06 requires lifespan/aging effects and separates development from aging. This claim is inherited neurodevelopmental disease. Its universal causal principles are used; local interpretation and exact universal quotations are explicit, rather than pretending the aging rubric already supplies a PKU-specific threshold."
  },
  "subclaim_matrix": {
    "subclaims": [
      {
        "id": "SC1",
        "statement": "Deficient PAH-mediated metabolism causes sustained phenylalanine elevation under ordinary dietary exposure.",
        "subclaim_type": "mechanism",
        "claimed_scope": "PAH-deficient hyperphenylalaninemia; concentration depends on residual activity and exposure.",
        "scope": "PAH-deficient hyperphenylalaninemia; concentration depends on residual activity and exposure.",
        "operational_scope": {
          "eligibility_is_outcome_independent": true,
          "baseline_definition": "PAH deficiency documented by appropriate biochemical and/or genetic findings before the outcome; inherited PAH deficiency is distinguished from other causes of hyperphenylalaninemia.",
          "severity_definition": "Retain the source-specific pretreatment biochemical category. Classical PKU historically includes untreated concentrations around or above 1200 micromol/L; this describes a study stratum, not an exact toxicity boundary or current treatment threshold.",
          "forbidden_selection": "Do not define susceptibility by later intellectual disability, response to diet, IQ, or brain-transport findings selected after the clinical outcome.",
          "candidate_modifiers": "Pretreatment severity, age and duration of exposure, nutritional adequacy and objectively recorded control. Brain uptake/genetic modifiers are hypotheses unless prospectively validated.",
          "diagnostic_endpoint_limit": "Historical IQ is informative but not equivalent to a complete contemporary intellectual-disability diagnosis, which also assesses adaptive functioning.",
          "falsifier": "Verified loss and restoration of PAH activity fail reproducibly to alter phenylalanine disposal with substrate exposure and other metabolic pathways controlled.",
          "endpoint": "PAH-dependent phenylalanine conversion and accumulation; biochemical function is the stated subclaim endpoint, not a surrogate proof of intellectual outcome.",
          "follow_up": "Metabolic changes assessed in the human functional findings and sustained after native-allele repair in the mouse study."
        },
        "key_evidence_anchor": "Enzyme-conversion evidence in humans and native-allele rescue in mice [8,14].",
        "rationale": "PAH restoration corrects the metabolic defect in a targeted model, consistent with human genotype and functional findings. This is not an IQ-risk prediction for every variant.",
        "governing_rubric": "universal framework with declared developmental-metabolic adaptation",
        "hsef_level": "Θ",
        "confidence": "High",
        "governing_cap_or_threshold": "Θ met for this stated prediction; Ω necessity and sufficiency across the full stated scope are not established in this dossier.",
        "level_dissent": {
          "alternative_level": "Ω",
          "source": "independent grading A (schema 5.3) and blind run R2 (Abacus AI Agent, self-described v5.3), 2026-09-27",
          "argument": "PAH deficiency producing persistent phenylalanine elevation on an ordinary diet approaches a metabolic identity: the enzymatic step is known, substrate accumulation follows from its absence, and no counterexample exists.",
          "why_not_adopted": "Ω is reserved for mechanisms whose rejection would require disregarding field-wide causal evidence, and is explicitly rare. Under weakest-link SC1 does not set the overall level, so Ω here is an assertion nothing downstream tests. The conservative assignment is preferred where the stronger one is free. Recorded disagreement, not a refutation of A.",
          "aggregate_effect": "none; weakest-link is set by SC2 under either value",
          "r2_argument": "R2: 'PAH is the sole hepatic enzyme for Phe hydroxylation; its loss is both necessary and sufficient.' R2's supporting record was mis-cited (PMID 12655542 resolves to an editorial; the intended PAHdb 2003 record is PMID 12655543) and that record reports that most pathogenic alleles act through misfolding with residual activity, which contradicts R2's wording that mutations 'abolish' activity.",
          "pass_02_note": "Pass-02 does not adopt Ω but records that the prior rationale ('Ω is reserved and rare') is not a framework blocker. The actual reason Θ is retained: the ledger does not contain human necessity-and-sufficiency evidence for this subclaim beyond one family [8] and one mouse editing study [14]; and SC1 does not bind under weakest-link. Deferred rather than resolved."
        }
      },
      {
        "id": "SC2",
        "statement": "The resulting sustained developmental phenylalanine exposure is a major cause of intellectual disability in untreated PAH-deficient PKU.",
        "subclaim_type": "primacy",
        "claimed_scope": "Developmental exposure in biochemically defined PKU, especially classical disease; incomplete penetrance and mild phenotypes remain in view.",
        "scope": "Developmental exposure in biochemically defined PKU, especially classical disease; incomplete penetrance and mild phenotypes remain in view.",
        "operational_scope": {
          "eligibility_is_outcome_independent": true,
          "baseline_definition": "PAH deficiency documented by appropriate biochemical and/or genetic findings before the outcome; inherited PAH deficiency is distinguished from other causes of hyperphenylalaninemia.",
          "severity_definition": "Retain the source-specific pretreatment biochemical category. Classical PKU historically includes untreated concentrations around or above 1200 micromol/L; this describes a study stratum, not an exact toxicity boundary or current treatment threshold.",
          "forbidden_selection": "Do not define susceptibility by later intellectual disability, response to diet, IQ, or brain-transport findings selected after the clinical outcome.",
          "candidate_modifiers": "Pretreatment severity, age and duration of exposure, nutritional adequacy and objectively recorded control. Brain uptake/genetic modifiers are hypotheses unless prospectively validated.",
          "diagnostic_endpoint_limit": "Historical IQ is informative but not equivalent to a complete contemporary intellectual-disability diagnosis, which also assesses adaptive functioning.",
          "falsifier": "In independently defined PAH-deficient infants, verified early and sustained phenylalanine control fails reproducibly to reduce subsequent intellectual disability despite adequate nutrition and comparable baseline disease and other causes; or a controlled, phenotype-relevant system shows that selectively changing phenylalanine does not alter injury while an independent variable fully accounts for it. Null results require precision sufficient to exclude the prespecified meaningful effect.",
          "endpoint": "Developmental intellectual disability; keep IQ, adaptive function, acute attention and animal behavior separately labeled.",
          "follow_up": "Childhood developmental exposure and later intellectual outcome; acute adult loading is supporting evidence only."
        },
        "key_evidence_anchor": "Affected-sibling prevention contrasts, specific add-back and controlled animal perturbations, with human discordance examined [1–14].",
        "rationale": "Pass-02: the causal pattern is predicted with high accuracy across untreated natural history, early-treatment sibling contrasts, timing and control dose-response, maternal exposure without offspring PAH deficiency, and specific add-back. The residual deficit of early-treated cohorts is accounted for by timing and control [3,5]. The protected untreated phenotype is a rare exception to intellectual-disability penetrance whose members often still show Phe-attributable signs [2,8,20]; its determinant is unresolved [7,21,22]. That blocks Ω, not Θ.",
        "governing_rubric": "universal framework with declared developmental-metabolic adaptation",
        "hsef_level": "Θ",
        "confidence": "High",
        "governing_cap_or_threshold": "Θ met: 'High predictive accuracy with minimal unresolved exceptions. The mechanism accounts for most major observations in its claimed scope.' Ω not met: 'Necessity AND sufficiency demonstrated ... no disqualifying contradictory data' fails on the unexplained protected untreated phenotype.",
        "level_resolution": {
          "competing_values": {
            "grading_A": "Θ",
            "grading_B": "Η",
            "grading_C_R2_blind": "Θ",
            "redteam_pass_01": "Η",
            "redteam_pass_02": "Θ"
          },
          "decisive_for_aggregate": true,
          "pass_01_record": {
            "competing_values": {
              "grading_A": "Θ",
              "grading_B": "Η"
            },
            "decisive_for_aggregate": true,
            "case_for_theta": "Written first, per the upward-first rule. Maternal PKU syndrome dissociates genotype from exposure: a fetus without PAH deficiency, exposed to maternal phenylalanine, sustains developmental injury, which is hard to explain on a gene-intrinsic account. Sibling comparisons hold family background more nearly fixed while varying treatment timing. Controlled phenylalanine add-back alters measurable function in treated patients. On this reading residual deficits in early-treated cohorts are a property of incomplete prevention and belong to SC3, leaving primacy with minimal unresolved exceptions.",
            "case_for_eta": "Θ requires minimal unresolved exceptions, and the cohort literature reports exceptions that are neither rare nor fully explained. Smith, Beasley and Ades report early-treated children remaining about eight points below revised IQ norms and conclude many continue to suffer mild neurological impairment. Azen and colleagues report arithmetic scores declining between ages six and twelve in ninety per cent of their cohort. Whether these residuals reflect imperfect metabolic control, pre-treatment exposure, or a component not driven by phenylalanine is unresolved — and the third possibility is exactly what the primacy subclaim asserts against.",
            "resolution": "Η",
            "resolution_rationale": "The Θ case depends on assigning every residual deficit to SC3. That assignment is plausible but undemonstrated, and the subclaim whose truth it presupposes is SC2 itself. Until an analysis partitions residual impairment between incomplete control, pre-treatment exposure and a phenylalanine-independent term, the exceptions sit inside the primacy claim and Θ overstates.",
            "what_would_move_it_to_theta": "A cohort analysis partitioning residual cognitive deficit in early-and-continuously-treated PKU by pre-treatment exposure window and lifetime phenylalanine control, showing the residual is fully accounted for without a phenylalanine-independent term."
          },
          "pass_02_resolution": "Θ",
          "pass_02_case_for_eta_restated": "Two distinct Η cases were posted. (i) Grading B: similar severe biochemistry and the same genotype can coexist with discordant intellectual outcomes [2,8], strengthened here by Ramus 1999 (42 untreated families, extensive overlap, same-genotype siblings discordant, no modifier found) [21] and by the failure of the brain-Phe explanation to reach significance for intelligence in its follow-up study [22]. (ii) Pass-01: early-treated cohorts remain about eight IQ points below norms [3] and arithmetic declines [5]; whether that residual has a Phe-independent term was said to be unresolved.",
          "pass_02_rationale": "Case (ii) is met by evidence already in the posted ledger, as far as observational data can meet it: in [3] the 46 children with the most favourable treatment had a social-class-standardised mean IQ of 112.6, similar to the regression estimate and to revised population norms, and the authors attribute the residual deficit to 'the difficulties in fully controlling the metabolic abnormality' (the posted resolution quoted this sentence without its causal clause); in [5] children kept below 900 µmol/L beyond age 10 showed no deficits except arithmetic, which declined between ages 6 and 12 in 90% of all the children in the study. Residual subtle deficits are also not the graded outcome (intellectual disability). Case (i) is a real exception, but a minimal one in the Θ sense: the primary literature describes intellectually normal untreated people as very rare [8] and an international search identified 16 living cases [20]; in the largest sibling series the untreated patients above IQ 70 still showed intellectual impairment [2]; the international series of 16 such people often found other neurological, psychological and behavioural problems [20]; the protected sister in [8] had white-matter reduction on MRI. The exception is to penetrance of the disability threshold, not to the causal effect of the exposure. Its determinant is unresolved, which is the named blocker for Ω. The maternal-PKU natural experiment [16,17,18,27] — absent from the posted ledger although invoked in its Θ case — adds exposure without offspring PAH deficiency, with offspring outcome graded by the timing of maternal control.",
          "what_would_move_it_back_to_eta": "Evidence that protection in untreated classical PKU reflects a Phe-independent factor that also governs outcome in treated patients, or a well-controlled analysis showing a residual deficit in optimally treated children that is not explained by timing, control or nutrition.",
          "what_would_move_it_to_omega": "A prospectively validated explanation of the protected untreated phenotype (for example measured brain Phe handling or a genetic modifier) that predicts intellectual outcome in an independent cohort, plus a necessity/sufficiency account of the downstream brain injury.",
          "not_rule_shopping": "The preregistered weakest-link rule (grading B's protocol) is unchanged. The aggregate moves only because SC2 moves; primary-subclaim and scope-matched return the same letter."
        },
        "governing_rule": "Ω blocked: sufficiency across the claimed scope is not deterministic (protected untreated phenotype, unexplained and not prospectively predicted). Θ met under pass-02 adjudication; see level_resolution."
      },
      {
        "id": "SC3",
        "statement": "Phenylalanine restriction begun in early infancy and sustained with nutritional adequacy can prevent the severe intellectual-disability phenotype of classical PKU.",
        "subclaim_type": "prevention",
        "claimed_scope": "Prevention during development in infants identified before disability, with documented treatment timing and sustained control; not late reversal or guaranteed normalization of every cognitive domain.",
        "scope": "Prevention during development in infants identified before disability, with documented treatment timing and sustained control; not late reversal or guaranteed normalization of every cognitive domain.",
        "operational_scope": {
          "eligibility_is_outcome_independent": true,
          "baseline_definition": "PAH deficiency documented by appropriate biochemical and/or genetic findings before the outcome; inherited PAH deficiency is distinguished from other causes of hyperphenylalaninemia.",
          "severity_definition": "Retain the source-specific pretreatment biochemical category. Classical PKU historically includes untreated concentrations around or above 1200 micromol/L; this describes a study stratum, not an exact toxicity boundary or current treatment threshold.",
          "forbidden_selection": "Do not define susceptibility by later intellectual disability, response to diet, IQ, or brain-transport findings selected after the clinical outcome.",
          "candidate_modifiers": "Pretreatment severity, age and duration of exposure, nutritional adequacy and objectively recorded control. Brain uptake/genetic modifiers are hypotheses unless prospectively validated.",
          "diagnostic_endpoint_limit": "Historical IQ is informative but not equivalent to a complete contemporary intellectual-disability diagnosis, which also assesses adaptive functioning.",
          "falsifier": "In independently defined PAH-deficient infants, verified early and sustained phenylalanine control fails reproducibly to reduce subsequent intellectual disability despite adequate nutrition and comparable baseline disease and other causes; or a controlled, phenotype-relevant system shows that selectively changing phenylalanine does not alter injury while an independent variable fully accounts for it. Null results require precision sufficient to exclude the prespecified meaningful effect.",
          "endpoint": "Avoidance of the severe developmental intellectual-disability phenotype; separately report IQ shifts and specific neuropsychological deficits.",
          "follow_up": "Start during early infancy, with actual start age and continuing control recorded; available cohorts extend through childhood/adolescence. No single sharp safe start date is inferred."
        },
        "key_evidence_anchor": "Early-treatment sibling and register results, longitudinal US cohort and developmental animal studies [2–5,12,13].",
        "rationale": "The severe untreated phenotype is preventable when exposure is controlled early. Lower average IQ or selective deficits are not the same outcome as severe intellectual disability, and late rescue is a separate claim.",
        "governing_rubric": "universal framework with declared developmental-metabolic adaptation",
        "hsef_level": "Θ",
        "confidence": "High",
        "governing_cap_or_threshold": "Θ met for this stated prediction; Ω necessity and sufficiency across the full stated scope are not established in this dossier."
      }
    ],
    "aggregation_rule": "weakest-link",
    "aggregation_preregistered": true,
    "aggregation_rationale": "Both the metabolic causal chain and prevention are asserted; the weakest required subclaim governs. Recorded before assigning scores in work/pku-preregistration.md, after initial orientation searching.",
    "primary_subclaim_id": "SC2",
    "aggregation_derivation": "Weakest-link over SC1=Θ, SC2=Θ, SC3=Θ returns Θ. The rule was preregistered in grading B's protocol before scoring and is unchanged by pass-02. The prior edition returned Η solely because SC2 was Η.",
    "aggregation_alternatives": {
      "weakest_link_would_return": "Θ",
      "primary_subclaim_would_return": "Θ",
      "scope_matched_would_return": "Θ",
      "note": "All three rules return Θ on this decomposition, so the letter is not rule-dependent. Blind run R2 preregistered scope-matched over a five-subclaim decomposition (adding generalization at Η and a downstream-mechanism subclaim at Ζ); its own weakest-link alternative (Ζ) came entirely from the mechanism subclaim, which the graded claim does not assert. R2's route is recorded as dissent in pass_02_r2_reading; it is not adopted."
    },
    "index_rule_deviation": "No index entry; the declared weakest-link rule is retained.",
    "pass_02_r2_reading": {
      "r2_decomposition": "SC1 existence Ω · SC2 primacy Θ · SC3 'sufficiency' (prevention) Θ · SC4 generalization Η · SC5 LNAA-transport mechanism Ζ",
      "r2_rule": "scope-matched (highest subclaim matching the central claim's scope)",
      "mapping_to_this_decomposition": "R2 SC1–SC3 map onto this edition's SC1–SC3 as Ω/Θ/Θ; weakest-link over them returns Θ.",
      "why_r2_rule_not_adopted": "R2 declared the claim conjunctive and said both clauses must hold, then chose a rule that takes the highest matching subclaim; SKILL.md Step 1: 'A conjunctive hypothesis is scored on the conjunction, not on its easier half.' R2 also tagged SC4 and SC5 'disease-class', contradicting its stated reason for excluding SC5.",
      "why_r2_sc4_not_adopted": "R2's SC4 Η and its Ω blocker rest on a '~37% genotype-phenotype discordance' derived from a '63% concordance' figure; the cited record's 63% is the share of pathogenic alleles that are missense mutations (claim audit C10: contradicted).",
      "why_r2_sc5_not_gating": "The graded claim asserts Phe accumulation as the cause, not a downstream pathway; a mechanism subclaim under weakest-link would score the claim on something it does not say. Downstream mediation stays a knowledge gap."
    }
  },
  "competing_models": {
    "models_evaluated": [
      {
        "rank_in_tournament": 1,
        "model_id": "M1",
        "is_nominal": true,
        "name": "PAH deficiency → phenylalanine accumulation → preventable developmental disability",
        "core_claim": "Sustained marked phenylalanine elevation caused by PAH-deficient phenylketonuria is a major cause of developmental intellectual disability, which can be prevented by early, sustained, nutritionally adequate dietary phenylalanine restriction.",
        "explains_what_nominal_does_not": "Nominal causal/prevention proposition.",
        "strongest_supporting_evidence": [
          "Specific add-back [1,9]",
          "Early-treatment sibling and longitudinal evidence [2–5]",
          "Controlled and genetically targeted animal results [12–14]",
          "Maternal exposure without offspring PAH deficiency, graded by timing of maternal control [16,17,18,27]",
          "Best-treated register subgroup at population norms [3]"
        ],
        "strongest_contradictory_evidence": [
          "Mild phenotypes and protected untreated classical cases constrain deterministic readings [6,8,15].",
          "Same-genotype discordance across 42 untreated families, no modifier found [21]"
        ],
        "hsef_level_for_this_model": "Θ",
        "rationale": "Pass-02: causal and preventive support meets Θ; the protected untreated phenotype is a rare penetrance exception whose determinant is unresolved (blocks Ω). Prior edition: Η."
      },
      {
        "rank_in_tournament": 2,
        "model_id": "M2",
        "is_nominal": false,
        "name": "Phenylalanine injury modified by development and multiple brain pathways",
        "core_claim": "Phe exposure is causal, with effects modified by timing, brain handling, nutrition and several downstream processes.",
        "explains_what_nominal_does_not": "Accommodates incomplete penetrance and residual domain-specific deficits, but does not claim they are fully explained.",
        "strongest_supporting_evidence": [
          "Timing/control [2–5]",
          "Transport and discordance [7,8]",
          "Partial biochemical/behavioral rescue [12–14]",
          "LNAA co-loading blocks the brain Phe rise and acute EEG slowing [23]",
          "Transport kinetics vary at similar blood Phe [22]"
        ],
        "strongest_contradictory_evidence": [
          "No prospectively validated explanation of the protected untreated phenotype [8]."
        ],
        "hsef_level_for_this_model": "Η",
        "rationale": "Broader explanatory structure, not an independently validated predictor. Adding unspecified modifiers cannot earn Θ or remove exceptions. Pass-02: re-ranked below the nominal. Its additional content — unvalidated modifiers of brain handling and nutrition — cannot score above the causal core it contains; brain-transport support is one small outcome-selected study and a same-group follow-up [7,22], plus a six-person loading experiment [23]."
      },
      {
        "rank_in_tournament": 3,
        "model_id": "M3",
        "is_nominal": false,
        "name": "Tyrosine shortage alone explains the neurological phenotype",
        "core_claim": "The phenotype is explained principally by low tyrosine rather than toxic Phe exposure.",
        "explains_what_nominal_does_not": "Emphasizes substrate supply for neurotransmitter synthesis.",
        "strongest_supporting_evidence": [
          "Baseline tyrosine–performance correlations [11] and monoamine deficiency [12]."
        ],
        "strongest_contradictory_evidence": [
          "Raising plasma tyrosine did not improve performance [11]; Phe lowering changed monoamines and behavior [12]."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "Plausible contributor, not a sufficient replacement for Phe causation. The negative short trial constrains its tested intervention, not every developmental tyrosine hypothesis."
      },
      {
        "rank_in_tournament": 4,
        "model_id": "M4",
        "is_nominal": false,
        "name": "Nonspecific nutritional benefit explains apparent dietary rescue",
        "core_claim": "Improved nutrition and care account for the apparent treatment effect without requiring a major Phe-specific effect.",
        "explains_what_nominal_does_not": "Nutrition-sensitive cognition and effects beyond blood Phe.",
        "strongest_supporting_evidence": [
          "Nutrient supplementation at high Phe improved a mouse memory task [13]; underrestriction and overrestriction correlate with outcome [3]."
        ],
        "strongest_contradictory_evidence": [
          "Specific Phe add-back [1,9] and genetic correction without wholesale diet replacement [14] are not explained by attention or food quality alone."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "Nutritional modification is real within the animal experiment; the exclusive explanation of human PKU disability is unsupported. Model-context benefit is not a human causal ceiling for the whole dossier."
      }
    ],
    "tournament_summary": "Pass-02: the nominal M1 ranks first at Θ; M2 (Phe injury modified by development and brain pathways) contains M1 and ranks second at Η because its added modifier content is not validated. Tyrosine-only and nutrition-only accounts remain at Γ. A gene-intrinsic, Phe-independent brain defect is not listed as a model because no retrieved evidence supports it; maternal PKU [16,18,27] and early-treatment rescue [2,3] contradict it. Blind run R2's rival list (LNAA depletion Ζ, oxidative/myelin Δ, critical period Ε) is treated as sub-mechanisms within M2, consistent with grading B's protocol instruction to distinguish compatible submechanisms from opposing models. The tournament did not set the level.",
    "study_separating_rank1_from_rank2": "No exclusive separating study exists for nested M1/M2. The study that would separate them is a prospective test of whether a measured brain-handling or genetic modifier predicts protection in untreated or poorly controlled PKU [7,21,22]. R2 named maternal PKU (Lenke & Levy) as separating direct Phe toxicity from LNAA depletion; pass-02 rejects that: the fetal brain is exposed across its own blood-brain barrier, so maternal PKU cannot discriminate those two submechanisms.",
    "nominal_wins_only_by_funding_artifact": false,
    "level_unchanged_by_tournament": true
  },
  "evidence_inventory": [
    {
      "evidence_id": "E1",
      "citation": "BICKEL H, GERRARD J, HICKMANS EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;265(6790):812-813.",
      "source_pointer": "PMID:13098090; DOI:10.1016/s0140-6736(53)90473-5; reference [1]",
      "source_n": 1,
      "claim_ids": [
        "C2",
        "C19"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Phenylalanine add-back changes neurological/behavioral state while much of the diet and care context remains fixed.",
      "what_it_does_not_show": "Single case, not neonatal prevention or reversal of intellectual disability.",
      "confounders_present": [
        "Uncontrolled single case",
        "Partial blinding",
        "High add-back dose",
        "Short behavioral endpoint"
      ],
      "verification": "verified",
      "verification_note": "Original two-page 1953 article read in a scanned primary-paper copy hosted by the James Lind Library; PubMed/Europe PMC metadata checked. PubMed has no abstract.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E2",
      "citation": "Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. Lancet. 1974;2(7880):540-544.",
      "source_pointer": "PMID:4140266; DOI:10.1016/s0140-6736(74)91873-x; reference [2]",
      "source_n": 2,
      "claim_ids": [
        "C3",
        "C4",
        "C19"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Earlier dietary treatment in affected siblings is associated with substantially better intellectual development.",
      "what_it_does_not_show": "Not randomized; ascertainment and birth-order changes in care remain.",
      "confounders_present": [
        "Ascertainment through impaired index case",
        "Birth order",
        "Historical comparison"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": true,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E3",
      "citation": "Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child. 1990;65(5):472-478.",
      "source_pointer": "PMID:2357082; DOI:10.1136/adc.65.5.472; reference [3]",
      "source_n": 3,
      "claim_ids": [
        "C5",
        "C6",
        "C19"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Early-treatment register links actual timing/control to IQ and describes residual deficits.",
      "what_it_does_not_show": "Observational treatment-quality analysis; does not isolate Phe from family/nutritional covariates.",
      "confounders_present": [
        "Treatment adherence",
        "Social environment",
        "Changing norms",
        "No randomized untreated infant arm"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E4",
      "citation": "Koch R, Azen CG, Friedman EG, et al. Preliminary report on the effects of diet discontinuation in PKU. J Pediatr. 1982;100(6):870-875.",
      "source_pointer": "PMID:7086586; DOI:10.1016/s0022-3476(82)80503-9; reference [4]",
      "source_n": 4,
      "claim_ids": [
        "C7"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Randomized continuation/discontinuation tests later childhood dietary dependence.",
      "what_it_does_not_show": "IQ difference is not statistically significant; positive school endpoints are not incident ID.",
      "confounders_present": [
        "Age six is after the neonatal window",
        "Endpoint multiplicity",
        "Protocol deviations in later programme follow-up"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "study_id": "US-PKU-Collaborative-Study"
    },
    {
      "evidence_id": "E5",
      "citation": "Azen CG, Koch R, Friedman EG, et al. Intellectual development in 12-year-old children treated for phenylketonuria. Am J Dis Child. 1991;145(1):35-39.",
      "source_pointer": "PMID:1985428; DOI:10.1001/archpedi.1991.02160010037012; reference [5]",
      "source_n": 5,
      "claim_ids": [
        "C8",
        "C19"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Longer childhood follow-up relates intellectual/achievement outcomes to metabolic history.",
      "what_it_does_not_show": "Achieved-control comparison is not randomized; same US programme as [4].",
      "confounders_present": [
        "Adherence confounding",
        "Parent IQ",
        "Programme overlap"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "study_id": "US-PKU-Collaborative-Study",
      "same_study_as_evidence": "E4"
    },
    {
      "evidence_id": "E6",
      "citation": "Weglage J, Pietsch M, Feldmann R, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res. 2001;49(4):532-536.",
      "source_pointer": "PMID:11264437; DOI:10.1203/00006450-200104000-00015; reference [6]",
      "source_n": 6,
      "claim_ids": [
        "C9"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Persistently mild biochemical elevations can coexist with normal-range intellectual outcomes.",
      "what_it_does_not_show": "Small cohort does not establish a universal safe concentration or current treatment policy.",
      "confounders_present": [
        "Small sample",
        "Selection",
        "Specific exposure range"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E7",
      "citation": "Möller HE, Weglage J, Wiedermann D, et al. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18(11):1184-1191.",
      "source_pointer": "PMID:9809507; DOI:10.1097/00004647-199811000-00004; reference [7]",
      "source_n": 7,
      "claim_ids": [
        "C11"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "MRS and an oral load characterize blood–brain phenylalanine transport variation.",
      "what_it_does_not_show": "Cognitive comparison is outcome-selected and not a prospective susceptibility validation.",
      "confounders_present": [
        "Small selected sample",
        "Intermediate endpoint",
        "Outcome-based selection"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E8",
      "citation": "Demirbas D, Waisbren SE, Bodamer O, et al. Two adult sisters with untreated phenylketonuria: Strikingly discordant clinical phenotype. Mol Genet Metab Rep. 2026;46:101304.",
      "source_pointer": "PMID:41853686; DOI:10.1016/j.ymgmr.2026.101304; reference [8]",
      "source_n": 8,
      "claim_ids": [
        "C1",
        "C12"
      ],
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Same PAH variants and similar severe biochemical phenotype occur with discordant cognition.",
      "what_it_does_not_show": "Two people cannot estimate penetrance; brain Phe and continuous infant exposure were unavailable.",
      "confounders_present": [
        "Case selection",
        "Missing brain Phe",
        "Incomplete early-life exposure measurements"
      ],
      "verification": "verified",
      "verification_note": "Complete original article text retrieved and read through Europe PMC fullTextXML, plus indexed primary abstract and metadata; no inference from the failed PubMed/PMC browser pages.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E9",
      "citation": "ten Hoedt AE, de Sonneville LM, Francois B, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011;34(1):165-171.",
      "source_pointer": "PMID:21153445; DOI:10.1007/s10545-010-9253-9; reference [9]",
      "source_n": 9,
      "claim_ids": [
        "C13"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Blinded Phe supplementation affects adult attention and mood.",
      "what_it_does_not_show": "Does not recreate developmental exposure or demonstrate intellectual disability.",
      "confounders_present": [
        "Nine participants",
        "Short duration",
        "Adult endpoint"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E10",
      "citation": "Trepp R, Muri R, Maissen-Abgottspon S, et al. Cognition after a 4-week high phenylalanine intake in adults with phenylketonuria - a randomized controlled trial. Am J Clin Nutr. 2024;119(4):908-916.",
      "source_pointer": "PMID:38569786; DOI:10.1016/j.ajcnut.2023.11.007; reference [10]",
      "source_n": 10,
      "claim_ids": [
        "C14"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Randomized adult loading did not worsen the primary working-memory-accuracy outcome beyond the noninferiority margin.",
      "what_it_does_not_show": "Not proof of childhood or lifelong safety; attention outcome differed.",
      "confounders_present": [
        "Adult selection",
        "Four-week exposure",
        "Endpoint-specific inference"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E11",
      "citation": "Smith ML, Hanley WB, Clarke JT, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch Dis Child. 1998;78(2):116-121.",
      "source_pointer": "PMID:9579151; DOI:10.1136/adc.78.2.116; reference [11]",
      "source_n": 11,
      "claim_ids": [
        "C15"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "narrows_rival",
      "what_it_shows": "Tyrosine rose without measured neuropsychological benefit.",
      "what_it_does_not_show": "Does not eliminate every developmental or downstream tyrosine-mediated mechanism.",
      "confounders_present": [
        "Short trial",
        "Mixed ages",
        "Plasma not brain tyrosine"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E12",
      "citation": "Winn SR, Scherer T, Thöny B, et al. Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice. Mol Genet Metab. 2018;123(1):6-20.",
      "source_pointer": "PMID:29331172; DOI:10.1016/j.ymgme.2017.10.009; reference [12]",
      "source_n": 12,
      "claim_ids": [
        "C16"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "qualifies",
      "what_it_shows": "Adult lowering by diet/gene therapy separates monoamine and nesting rescue from persistent learning deficits.",
      "what_it_does_not_show": "Biochemical rescue is not cognitive reversal or evidence of failed neonatal prevention.",
      "confounders_present": [
        "Species/background",
        "Adult timing",
        "Gene-transfer component"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E13",
      "citation": "Bruinenberg VM, van Vliet D, van der Goot E, et al. Long-term dietary intervention with low Phe and/or a specific nutrient combination improve certain aspects of brain functioning in phenylketonuria (PKU). PLoS One. 2019;14(3):e0213391.",
      "source_pointer": "PMID:30875376; DOI:10.1371/journal.pone.0213391; reference [13]",
      "source_n": 13,
      "claim_ids": [
        "C17"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Controlled low-Phe and nutrient diets improve some learning/behavioral endpoints.",
      "what_it_does_not_show": "Incomplete task rescue and benefit of nutrients at high Phe constrain a Phe-only explanation of every readout.",
      "confounders_present": [
        "Species/background",
        "Diet composition",
        "Multiple tasks",
        "Juvenile rather than neonatal timing"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E14",
      "citation": "Gautier MK, King K, Han Y, et al. In vivo adenine base editing rescues brain biochemistry and improves motor deficits in a common phenylketonuria variant. Mol Ther Adv. 2026;34(2):201760.",
      "source_pointer": "PMID:42290942; DOI:10.1016/j.omta.2026.201760; reference [14]",
      "source_n": 14,
      "claim_ids": [
        "C1",
        "C18",
        "C19"
      ],
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Correction of a native pathogenic PAH variant reduces Phe and improves motor phenotype.",
      "what_it_does_not_show": "Motor rescue is not human intellectual-disability prevention.",
      "confounders_present": [
        "Humanized mouse variant",
        "Age and delivery context",
        "Motor endpoint"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E15",
      "citation": "Costello PM, Beasley MG, Tillotson SL, et al. Intelligence in mild atypical phenylketonuria. Eur J Pediatr. 1994;153(4):260-263.",
      "source_pointer": "PMID:8194559; DOI:10.1007/bf01954515; reference [15]",
      "source_n": 15,
      "claim_ids": [
        "C10"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Milder biochemical phenotypes can show IQ shifts despite not uniformly producing severe disability.",
      "what_it_does_not_show": "Different exposure/age cohorts do not yield a universal toxicity threshold.",
      "confounders_present": [
        "Observational severity/control",
        "Historical testing",
        "Potential programme overlap"
      ],
      "verification": "verified",
      "verification_note": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      }
    },
    {
      "evidence_id": "E16",
      "citation": "Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med. 1980;303(21):1202-1208.",
      "source_pointer": "PMID:7421947; DOI:10.1056/NEJM198011203032104; reference [16]",
      "source_n": 16,
      "claim_ids": [
        "C22"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Offspring exposed in utero to high maternal phenylalanine have greatly increased mental retardation, microcephaly and heart disease, correlated with maternal levels.",
      "what_it_does_not_show": "Retrospective survey with literature cases; case-finding bias possible (the authors argue it cannot explain the result); offspring genotype not individually reported in the abstract.",
      "confounders_present": [
        "Ascertainment through affected offspring",
        "Literature-compiled cases",
        "Maternal diet not controlled"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27 (correct PMID 7421947; R2 cited 7421961, which is an unrelated NEJM chest-pain paper). Full text not accessible (publisher 403); table figures not used.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E17",
      "citation": "Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics. 2003;112(6 Pt 2):1523-1529.",
      "source_pointer": "PMID:14654658; reference [17]",
      "source_n": 17,
      "claim_ids": [
        "C23"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Maternal dietary control achieved before or early in pregnancy is associated with optimal offspring outcome; morbidity falls with pre- and periconceptional control.",
      "what_it_does_not_show": "Achieved control is not randomized; outcome here is birth outcome, with cognition reported in the companion report [18].",
      "confounders_present": [
        "Adherence-related confounding",
        "Timing of control is self-selected"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27 (correct PMID 14654658; R2 cited 14654655, which is an NICHD historical note). Same study as [18].",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E18",
      "citation": "Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA. 2000;283(6):756-762.",
      "source_pointer": "PMID:10683054; DOI:10.1001/jama.283.6.756; reference [18]",
      "source_n": 18,
      "claim_ids": [
        "C24"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Offspring cognitive index falls with the number of weeks before maternal metabolic control; offspring of mothers controlled before pregnancy score in the normal range.",
      "what_it_does_not_show": "Observational dose-timing within a prospective study; not randomized; four-year outcome only.",
      "confounders_present": [
        "Adherence and social confounding",
        "Timing of control self-selected"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Added by pass-02 (omission audit).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E19",
      "citation": "Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1-2):63-70.",
      "source_pointer": "PMID:17591452; DOI:10.1016/j.ymgme.2007.05.006; reference [19]",
      "source_n": 19,
      "claim_ids": [
        "C25"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "Pooled within-study correlations show lower IQ with higher blood phenylalanine in early-treated patients during childhood.",
      "what_it_does_not_show": "Correlational pooling of overlapping cohorts; its stated aim was to validate blood Phe as a trial biomarker; not a causal estimate.",
      "confounders_present": [
        "Overlapping cohorts with [3,5]",
        "Ecological heterogeneity"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Carried from R2 with corrected title ('systematic literature review'); R2's evidence pointer PMID 17224690 was wrong.",
      "source_tier": "B",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E20",
      "citation": "van Vliet D, van Wegberg AMJ, Ahring K, et al. Untreated PKU patients without intellectual disability: what do they teach us? Nutrients. 2019;11(11):2572.",
      "source_pointer": "PMID:31731404; DOI:10.3390/nu11112572; reference [20]",
      "source_n": 20,
      "claim_ids": [
        "C26"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "An international search found 16 living untreated or late-diagnosed patients with near-normal intellect despite high Phe, most with other neurological, psychological or behavioural problems.",
      "what_it_does_not_show": "A selected case series; cannot estimate frequency; no mechanism established.",
      "confounders_present": [
        "Selection by favourable outcome",
        "Heterogeneous histories"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Carried from grading A's ledger (union reconciliation flagged by pass-01).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E21",
      "citation": "Ramus SJ, Forrest SM, Pitt DD, Cotton RG. Genotype and intellectual phenotype in untreated phenylketonuria patients. Pediatr Res. 1999;45(4 Pt 1):474-481.",
      "source_pointer": "PMID:10203137; DOI:10.1203/00006450-199904010-00004; reference [21]",
      "source_n": 21,
      "claim_ids": [
        "C27"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "In untreated PKU, predicted PAH activity relates to intellect but with extensive overlap; same-genotype siblings can differ markedly, not explained by diet.",
      "what_it_does_not_show": "Does not identify the modifier; historical intellectual assessment.",
      "confounders_present": [
        "Historical IQ measures",
        "Family ascertainment"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Added by pass-02 (omission audit, evidence toward Η).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E22",
      "citation": "Weglage J, Wiedermann D, Denecke J, et al. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol. 2001;50(4):463-467.",
      "source_pointer": "PMID:11601498; DOI:10.1002/ana.1226; reference [22]",
      "source_n": 22,
      "claim_ids": [
        "C28"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M2"
      ],
      "evidence_class": "Weak",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "qualifies",
      "what_it_shows": "Brain Phe and transport kinetics vary widely at similar blood Phe and track white-matter abnormality.",
      "what_it_does_not_show": "Correlations with intelligence only approached significance; small sample; same group as [7], so not an independent replication.",
      "confounders_present": [
        "Small N",
        "Same research group as [7]",
        "Outcome known at measurement"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Added by pass-02 (omission audit, evidence toward Η).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E23",
      "citation": "Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8):1169-1178.",
      "source_pointer": "PMID:10207169; DOI:10.1172/JCI5017; reference [23]",
      "source_n": 23,
      "claim_ids": [
        "C29"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "In adults with PKU, an oral Phe load raises brain Phe with acute EEG slowing; co-loading other large neutral amino acids blocks both.",
      "what_it_does_not_show": "Six adults, acute endpoint; a mechanism/brain-handling result, not developmental ID.",
      "confounders_present": [
        "Small N",
        "Acute EEG endpoint",
        "Single sex"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract and JCI full text (methods and results sections) read 2026-09-27. Carried from R2 (its C7, marked unverified there).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E24",
      "citation": "Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370(9586):504-510.",
      "source_pointer": "PMID:17693179; DOI:10.1016/S0140-6736(07)61234-3; reference [24]",
      "source_n": 24,
      "claim_ids": [
        "C30"
      ],
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "A pharmacological agent that augments residual PAH activity lowers blood Phe relative to placebo.",
      "what_it_does_not_show": "Primary endpoint was blood Phe only; no cognitive or developmental endpoint — cannot carry SC2 or SC3 (cap 4).",
      "confounders_present": [
        "Biomarker-only endpoint",
        "Responder-enriched population"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27 (correct PMID 17693179; R2 cited 17693178, which is the BAFTA warfarin trial). Recorded to document why R2's pharmacological line is not adopted.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E25",
      "citation": "Harding CO, Amato RS, Stuy M, et al. Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab. 2018;124(1):20-26.",
      "source_pointer": "PMID:29628378; DOI:10.1016/j.ymgme.2018.03.003; reference [25]",
      "source_n": 25,
      "claim_ids": [
        "C31"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1",
        "M2"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "null",
      "what_it_shows": "Randomized withdrawal of an enzyme-substitution therapy raised blood Phe within 8 weeks without significant change in neuropsychiatric or mood endpoints.",
      "what_it_does_not_show": "Eight-week adult discontinuation; the authors suggest duration or tools were inadequate; says nothing about developmental ID.",
      "confounders_present": [
        "Short duration",
        "Adult population",
        "Secondary endpoints"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract and open-access full text (results/discussion) read 2026-09-27. Added by pass-02 as the randomized pharmacological test with a functional readout (evidence toward a lower grade for adult extensions).",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E26",
      "citation": "Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417-1427.",
      "source_pointer": "PMID:20971365; DOI:10.1016/S0140-6736(10)60961-0; reference [26]",
      "source_n": 26,
      "claim_ids": [
        "C32"
      ],
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Field framing: untreated classic PKU leads to profound irreversible disability and early diet prevents most neuropsychological complications.",
      "what_it_does_not_show": "A review; used only for the Divergence implied level, never for an experimental result.",
      "confounders_present": [
        "Review, not primary data"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Carried from R2 as Tier B field framing.",
      "source_tier": "B",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    },
    {
      "evidence_id": "E27",
      "citation": "Levy HL, Lobbregt D, Sansaricq C, Snyderman SE. Comparison of phenylketonuric and nonphenylketonuric sibs from untreated pregnancies in a mother with phenylketonuria. Am J Med Genet. 1992;44(4):439-442.",
      "source_pointer": "PMID:1442884; DOI:10.1002/ajmg.1320440411; reference [27]",
      "source_n": 27,
      "claim_ids": [
        "C34"
      ],
      "relates_to_subclaims": [
        "SC2"
      ],
      "favors_models": [
        "M1"
      ],
      "evidence_class": "Weak",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "A PKU and a non-PKU child from untreated pregnancies of one mother were both microcephalic and intellectually impaired; fetal PAH offered little protection.",
      "what_it_does_not_show": "Two children; case report.",
      "confounders_present": [
        "Single family"
      ],
      "verification": "verified",
      "verification_note": "PubMed abstract read 2026-09-27. Added by pass-02 to source the offspring-genotype step of the maternal-PKU argument.",
      "source_tier": "A",
      "direct_human_ID_prevention_comparison": false,
      "citation_context": {
        "retrieved": false,
        "supporting_count": null,
        "mentioning_count": null,
        "contrasting_count": null,
        "notable_contrasting_statements": []
      },
      "added_in": "redteam pass-02, 2026-09-27"
    }
  ],
  "verification_summary": {
    "load_bearing_claims_checked": 35,
    "verified": 35,
    "unverified": 0,
    "contradicted": 0,
    "note": "Every registered claim was re-checked in pass-02 against the primary record named (abstract unless stated). Letter grades and causal synthesis remain reviewer judgments. Contradicted and unverifiable figures from input C were dropped rather than registered; they are listed in redteam/claim-audit.md."
  },
  "factual_issues_found": [
    {
      "issue": "RCT metadata does not make every analysis randomized.",
      "resolution": "Azen [5] is an achieved-control follow-up within the programme of [4], not a second independent randomized estimate."
    },
    {
      "issue": "Bickel has no indexed abstract.",
      "resolution": "Read the original two-page article before using its challenge details."
    },
    {
      "issue": "An older mild-HPA paper advises no treatment below a historical threshold.",
      "resolution": "Use its observed outcome, not its historical treatment advice, as evidence; this review does not prescribe a threshold."
    },
    {
      "issue": "Posted SC2 resolution quoted source [3]'s conclusion without its causal clause.",
      "quoted_text": "Smith, Beasley and Ades report early-treated children remaining approximately eight points below revised IQ norms, concluding that many continue to suffer a mild degree of neurological impairment.",
      "source_says": "'The data suggest that many children who are treated early continue to suffer a mild degree of neurological impairment because of the difficulties in fully controlling the metabolic abnormality'; 46 best-treated children had mean IQ 112.6, similar to the regression estimate and revised norms.",
      "source_pointer": "PMID 2357082",
      "affects_score": true,
      "action": "scored-on-corrected-understanding",
      "resolution": "SC2 re-adjudicated in pass-02 (Η → Θ); see level_resolution."
    },
    {
      "issue": "Posted Divergence used the reviewer's own level as the 'implied' level.",
      "quoted_text": "Reviewer-mapped implied Η − assessed Η = 0, Aligned.",
      "source_says": "Framework: the implied level is what a competent reader would infer from how the field presents the hypothesis. Field framing [8,26] implies Θ.",
      "source_pointer": "hsef-framework.md, Divergence",
      "affects_score": false,
      "action": "logged",
      "resolution": "Divergence recomputed from field framing: implied Θ, assessed Θ, Aligned."
    },
    {
      "issue": "Posted 'case for Θ' invoked maternal PKU with no maternal-PKU source in the ledger.",
      "quoted_text": "Maternal PKU syndrome dissociates genotype from exposure ...",
      "source_says": "Supported by [16,17,18,27], now added.",
      "source_pointer": "PMIDs 7421947, 14654658, 10683054, 1442884",
      "affects_score": true,
      "action": "scored-on-corrected-understanding",
      "resolution": "Sources added; claims C22–C24, C34."
    },
    {
      "issue": "Blind run R2 (input C) — identifier and claim defects (not carried into this edition).",
      "quoted_text": "C10: 'Genotype-phenotype concordance in PAH-deficient PKU is approximately 63%'; C2: 'IQ typically below 50 in virtually all affected individuals'; 8 of 17 ledger PMIDs.",
      "source_says": "PAHdb 2003 (PMID 12655543): 63% of pathogenic alleles are missense mutations; Smith & Wolff 1974: about 1 in 6 or 7 untreated classical patients reach IQ >70; the eight PMIDs resolve to unrelated papers (identifier-audit.md).",
      "source_pointer": "redteam/identifier-audit.md; redteam/claim-audit.md",
      "affects_score": false,
      "action": "logged",
      "resolution": "R2 figures dropped or re-verified from correct records; R2's letter recorded as a third reading."
    }
  ],
  "cap_rules_applied": [
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.",
      "specific_trigger": "Human treatment and in-vivo phenotypes accompany molecular evidence.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC1",
      "cap": "Β",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.",
      "specific_trigger": "Cohort correlations are not the complete evidence set; they converge with specific and controlled interventions.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Overexpression in model systems caps at Γ",
      "specific_trigger": "The gene-transfer arm of [12] is restricted to model evidence; native-allele repair [14] and human interventions carry distinct support.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "Blood Phe and monoamines are not equated with prevented human ID. Intellectual, behavioral and biochemical endpoints are labeled separately.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Seeding or forced-transfer paradigms cap at Γ",
      "specific_trigger": "Oral Phe loading is not a claim of endogenous pathological propagation; its acute endpoint is retained.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Genetic evidence in familial / syndromic cases generalized to sporadic disease is scope-restricted.",
      "specific_trigger": "The target is inherited PAH deficiency; no inference to all intellectual disability is made.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.",
      "specific_trigger": "Human treatment and in-vivo phenotypes accompany molecular evidence.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Β",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.",
      "specific_trigger": "Cohort correlations are not the complete evidence set; they converge with specific and controlled interventions.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Overexpression in model systems caps at Γ",
      "specific_trigger": "The gene-transfer arm of [12] is restricted to model evidence; native-allele repair [14] and human interventions carry distinct support.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "Blood Phe and monoamines are not equated with prevented human ID. Intellectual, behavioral and biochemical endpoints are labeled separately.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Seeding or forced-transfer paradigms cap at Γ",
      "specific_trigger": "Oral Phe loading is not a claim of endogenous pathological propagation; its acute endpoint is retained.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC2",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Genetic evidence in familial / syndromic cases generalized to sporadic disease is scope-restricted.",
      "specific_trigger": "The target is inherited PAH deficiency; no inference to all intellectual disability is made.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.",
      "specific_trigger": "Human treatment and in-vivo phenotypes accompany molecular evidence.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Β",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.",
      "specific_trigger": "Cohort correlations are not the complete evidence set; they converge with specific and controlled interventions.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Overexpression in model systems caps at Γ",
      "specific_trigger": "The gene-transfer arm of [12] is restricted to model evidence; native-allele repair [14] and human interventions carry distinct support.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "Blood Phe and monoamines are not equated with prevented human ID. Intellectual, behavioral and biochemical endpoints are labeled separately.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Seeding or forced-transfer paradigms cap at Γ",
      "specific_trigger": "Oral Phe loading is not a claim of endogenous pathological propagation; its acute endpoint is retained.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": false,
      "trigger_text_quoted": "Genetic evidence in familial / syndromic cases generalized to sporadic disease is scope-restricted.",
      "specific_trigger": "The target is inherited PAH deficiency; no inference to all intellectual disability is made.",
      "resulting_ceiling": null
    },
    {
      "subclaim_id": "R2 pharmacological line (inference to SC2 from Phe-endpoint trials alone)",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": true,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "Sapropterin [24] and pegvaliase (PRISM) trials counted by R2 as an independent causal line report blood Phe as the primary endpoint; the randomized pegvaliase discontinuation trial [25] found no significant neuropsychiatric difference at 8 weeks.",
      "resulting_ceiling": "Γ",
      "scope_note": "Binds the inference from this evidence class alone; it is not re-applied to the convergent set (pitfall 21). Recorded because R2's independence basis counted this class as a line."
    }
  ],
  "cap_precedence_resolutions": [
    {
      "subclaim_scope_cap_binds_on": "The transgene/model and biochemical-only legs considered in isolation.",
      "subclaim_scope_threshold_binds_on": "The convergent human developmental/functional claim.",
      "resolution": "Keep model and biomarker endpoints local; do not reapply their individual ceilings to an independently convergent set. Native-allele editing is distinguished from the older ectopic gene-transfer arm."
    },
    {
      "collision": "R2 counted Phe-lowering drug trials (biomarker endpoints, cap 4) as an independent line supporting an upper-ladder level.",
      "subclaim_scope_cap_binds_on": "The pharmacological Phe-endpoint trials considered as a stand-alone line for SC2.",
      "subclaim_scope_threshold_binds_on": "SC1 (PAH-pathway restoration lowers Phe), where Phe is the stated endpoint.",
      "resolution": "Counted for SC1 only; not an independence line for SC2/SC3. No effect on the convergent SC2 set.",
      "note": "Never resolve a collision silently."
    }
  ],
  "boundary_check_BGD": [
    {
      "subclaim_id": "SC1",
      "field_valid_perturbation_quote": "Where deliberate human perturbation is unethical or impossible, the field-valid equivalents are: Mendelian randomization with a plausible instrument, natural experiments, dose-response across independent populations, withdrawal-and-rechallenge at population scale, and therapeutic perturbation of the mechanism with a hard clinical endpoint.",
      "quote_source": "Universal framework; no invented quotation from aging rubric.",
      "qualifying_evidence_present": "yes",
      "qualifying_evidence_citation": "[8,14] metabolic loss/restoration; [1] substrate manipulation.",
      "gamma_hard_rules_triggered": [
        "No isolated association, biochemical assay or animal readout is used as the entire clinical causal set."
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "yes",
      "perturbation_result_note": "Positive relevance is to the stated subclaim; adult attention, motor function and blood Phe are not counted as direct human ID prevention.",
      "ceiling_from_boundary_check": "Δ or higher"
    },
    {
      "subclaim_id": "SC2",
      "field_valid_perturbation_quote": "Where deliberate human perturbation is unethical or impossible, the field-valid equivalents are: Mendelian randomization with a plausible instrument, natural experiments, dose-response across independent populations, withdrawal-and-rechallenge at population scale, and therapeutic perturbation of the mechanism with a hard clinical endpoint.",
      "quote_source": "Universal framework; no invented quotation from aging rubric.",
      "qualifying_evidence_present": "yes",
      "qualifying_evidence_citation": "[2] developmental clinical natural experiment; [1,9,12–14] endpoint-limited complementary perturbation.",
      "gamma_hard_rules_triggered": [
        "No isolated association, biochemical assay or animal readout is used as the entire clinical causal set."
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "yes",
      "perturbation_result_note": "Positive relevance is to the stated subclaim; adult attention, motor function and blood Phe are not counted as direct human ID prevention.",
      "ceiling_from_boundary_check": "Δ or higher"
    },
    {
      "subclaim_id": "SC3",
      "field_valid_perturbation_quote": "Where deliberate human perturbation is unethical or impossible, the field-valid equivalents are: Mendelian randomization with a plausible instrument, natural experiments, dose-response across independent populations, withdrawal-and-rechallenge at population scale, and therapeutic perturbation of the mechanism with a hard clinical endpoint.",
      "quote_source": "Universal framework; no invented quotation from aging rubric.",
      "qualifying_evidence_present": "yes",
      "qualifying_evidence_citation": "[2] early treatment contrast, supported by longitudinal treatment evidence [3–5].",
      "gamma_hard_rules_triggered": [
        "No isolated association, biochemical assay or animal readout is used as the entire clinical causal set."
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "yes",
      "perturbation_result_note": "Positive relevance is to the stated subclaim; adult attention, motor function and blood Phe are not counted as direct human ID prevention.",
      "ceiling_from_boundary_check": "Δ or higher"
    }
  ],
  "thresholds_tested": [
    {
      "subclaim_id": "SC1",
      "threshold": "Δ",
      "requirement_quoted": "First field-valid causal perturbation threshold crossed. At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype. Exact definition of \"field-valid\" is rubric-specific.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Human loss-of-function/conversion findings and targeted restoration in native-allele mice establish a metabolic causal perturbation [8,14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC1",
      "threshold": "Ε",
      "requirement_quoted": "Context-specific causality established. The mechanism is causally operative in a defined context, subtype, stage, or model — but generalization to the full claimed scope fails.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "A PAH-deficient biochemical context is defined independently of cognition [8,14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC1",
      "threshold": "Ζ",
      "requirement_quoted": "Multiple independent causal lines converge. Replication across at least two relevant systems, with major alternative models narrowed but not excluded.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Human functional genetics converges with controlled native-allele repair and exposure manipulation [1,8,14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC1",
      "threshold": "Η",
      "requirement_quoted": "Strong convergent causal evidence with intervention-sensitive trajectory change and no major unresolved upstream/downstream contradiction within the claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Phe disposal changes with targeted correction and substrate intervention [1,14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC1",
      "threshold": "Θ",
      "requirement_quoted": "High predictive accuracy with minimal unresolved exceptions. The mechanism accounts for most major observations in its claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "The loss-of-function/accumulation relation is reproducible and functionally specified; variant severity changes degree, not causal direction [8,14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC1",
      "threshold": "Ω",
      "requirement_quoted": "Necessity AND sufficiency demonstrated, reproducibility across systems, no disqualifying contradictory data. Reserved for mechanisms whose rejection would require disregarding the weight of field-wide causal evidence. Rare. Most biomedical hypotheses will never reach this level.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "no",
      "supporting_evidence": [
        "This bounded dossier does not exhaustively demonstrate necessity and sufficiency across all residual-activity, substrate and human variant contexts."
      ],
      "what_would_cross_it": "A precisely defined necessity-and-sufficiency proposition tested across its biological scope; another positive biomarker or dietary cohort alone is insufficient."
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Δ",
      "requirement_quoted": "First field-valid causal perturbation threshold crossed. At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype. Exact definition of \"field-valid\" is rubric-specific.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Early intervention changes intellectual outcome in a relevant human natural experiment [2], with specific functional exposure challenges [1,9]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Ε",
      "requirement_quoted": "Context-specific causality established. The mechanism is causally operative in a defined context, subtype, stage, or model — but generalization to the full claimed scope fails.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Severity and developmental timing are explicit [2,3,6,15]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Ζ",
      "requirement_quoted": "Multiple independent causal lines converge. Replication across at least two relevant systems, with major alternative models narrowed but not excluded.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Human developmental intervention, molecule-specific add-back and controlled animal experiments narrow different errors [1–5,9,12–14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Η",
      "requirement_quoted": "Strong convergent causal evidence with intervention-sensitive trajectory change and no major unresolved upstream/downstream contradiction within the claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Convergent evidence supports a causal developmental trajectory rather than a passive blood marker [1–5,12–14]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Θ",
      "requirement_quoted": "High predictive accuracy with minimal unresolved exceptions. The mechanism accounts for most major observations in its claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Untreated natural history, early-treatment sibling contrast and register dose-response are predicted by the exposure [2,3,5,19].",
        "Residual deficit in early-treated cohorts is accounted for by timing and control: best-treated subgroup at population norms [3]; no deficit except arithmetic with Phe <900 beyond age 10 [5].",
        "Exposure without offspring PAH deficiency injures development, graded by timing of maternal control [16,17,18,27].",
        "The protected untreated phenotype is rare and its members often still show Phe-attributable signs [2,8,20]; its determinant is unresolved [7,21,22] — a minimal unresolved exception, not a contradiction."
      ],
      "what_would_cross_it": "",
      "pass_01_status": "no — Not established: severe biochemical/genotypic similarity can coexist with markedly different cognition; no validated explanation removes the discordance [8]. Blood–brain observations [7] are a candidate explanation, not a prospective exclusion rule.",
      "pass_02_note": "Moved from 'no' (pass-01/B) to 'yes' by pass-02; see subclaim_matrix SC2 level_resolution."
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Ω",
      "requirement_quoted": "Necessity AND sufficiency demonstrated, reproducibility across systems, no disqualifying contradictory data. Reserved for mechanisms whose rejection would require disregarding the weight of field-wide causal evidence. Rare. Most biomedical hypotheses will never reach this level.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "no",
      "supporting_evidence": [
        "Necessity (early removal prevents) and sufficiency in a non-PKU genotype (maternal exposure) are shown at population scale [2,3,16,18], but sufficiency is not deterministic: untreated classical PKU can coexist with preserved intellect [2,8,20,21]."
      ],
      "what_would_cross_it": "A prospectively validated predictor of protection in untreated or poorly controlled PKU, tested in an independent cohort, plus a necessity/sufficiency account of the downstream injury.",
      "added_in": "redteam pass-02"
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Δ",
      "requirement_quoted": "First field-valid causal perturbation threshold crossed. At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype. Exact definition of \"field-valid\" is rubric-specific.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Early treatment materially changes intellectual outcome in affected-sibling contrasts [2]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Ε",
      "requirement_quoted": "Context-specific causality established. The mechanism is causally operative in a defined context, subtype, stage, or model — but generalization to the full claimed scope fails.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Early infancy and continued adequate nutrition/control define the tested preventive scope [2,3]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Ζ",
      "requirement_quoted": "Multiple independent causal lines converge. Replication across at least two relevant systems, with major alternative models narrowed but not excluded.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Human developmental results converge with isolated Phe challenges and animal timing/nutrient perturbations; supporting endpoints retain their limits [1–5,9,12,13]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Η",
      "requirement_quoted": "Strong convergent causal evidence with intervention-sensitive trajectory change and no major unresolved upstream/downstream contradiction within the claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "Diet begun before major developmental injury alters the clinical trajectory [2–5]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Θ",
      "requirement_quoted": "High predictive accuracy with minimal unresolved exceptions. The mechanism accounts for most major observations in its claimed scope.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "yes",
      "supporting_evidence": [
        "The specific prediction of preventing the severe untreated developmental phenotype is repeatedly supported; residual smaller deficits are reported rather than relabeled as complete normalization [2–5]."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Ω",
      "requirement_quoted": "Necessity AND sufficiency demonstrated, reproducibility across systems, no disqualifying contradictory data. Reserved for mechanisms whose rejection would require disregarding the weight of field-wide causal evidence. Rare. Most biomedical hypotheses will never reach this level.",
      "requirement_source": "hsef-framework.md; universal definition, verbatim",
      "satisfied": "no",
      "supporting_evidence": [
        "A dietary intervention is not necessary if other means control Phe, and treatment does not guarantee every cognitive outcome. Necessity and sufficiency of the complete broad claim are not demonstrated."
      ],
      "what_would_cross_it": "A precisely defined necessity-and-sufficiency proposition tested across its biological scope; another positive biomarker or dietary cohort alone is insufficient."
    }
  ],
  "generalization_check": {
    "generalization_tested": "yes",
    "context_boundary_mapped": "partly",
    "internal_negative_controls": [
      "WT and diet-composition controls in [13]; variant correction in [14]."
    ],
    "observed_unresolved_boundaries": [
      "Protected untreated classical-PKU cases [8].",
      "Mild concentration-range/age differences [6,15].",
      "Adult primary endpoint null/noninferiority [10].",
      "Biochemical and behavioral rescue without cognitive reversal [12].",
      "Same-genotype discordance in 42 untreated families [21]; brain-transport explanation not significant for IQ [22].",
      "Randomized pharmacological Phe withdrawal without 8-week neuropsychiatric change in adults [25]."
    ],
    "note": "Timing and severity are recorded before outcomes. The unexplained discordance remains inside the biological scope; it is not resolved by naming susceptibility.",
    "pass_02_note": "Lower boundary mapped by untreated mild hyperphenylalaninaemia with normal outcome [6]; upper-severity exceptions remain unexplained and block Ω."
  },
  "falsification_patterns_met": [],
  "falsification_audit": [
    {
      "subclaim_id": "SC2",
      "pattern": "Matched genotype and similar high blood Phe with discordant intellectual outcome",
      "triggered": true,
      "interpretation": "Contradicts an invariably sufficient blood/genotype model, not the existence of a major causal contribution. Pass-02: counted once, at Ω (blocks necessity-and-sufficiency); treated as a minimal unresolved exception at Θ because it is rare and its members often still show Phe-attributable signs [2,8,20]. Prior edition counted it at Θ.",
      "downgrade_applied": false,
      "threshold_effect": "Counted once at Ω; no second subtraction."
    },
    {
      "subclaim_id": "SC3",
      "pattern": "Late lowering fails to reverse severe cognitive impairment",
      "triggered": false,
      "interpretation": "This is outside the early-prevention prediction but must be retained against the stronger reversal claim [12].",
      "downgrade_applied": false
    },
    {
      "subclaim_id": "SC2",
      "pattern": "Adult loading does not worsen every measured domain",
      "triggered": false,
      "interpretation": "A four-week adult primary endpoint is not the developmental ID endpoint; it constrains broad adult extensions [10].",
      "downgrade_applied": false
    },
    {
      "subclaim_id": "SC2",
      "pattern": "Randomized Phe withdrawal (pegvaliase discontinuation) without neuropsychiatric deterioration at 8 weeks",
      "triggered": false,
      "interpretation": "A null on short adult secondary endpoints [25]; constrains adult acute extensions, like [10]; not a test of developmental ID.",
      "downgrade_applied": false
    }
  ],
  "pitfalls_flagged": [
    {
      "subclaim_id": "SC1/SC2",
      "pitfall": "8. Confirmation by biomarker",
      "where": "Do not promote lower blood Phe, restored monoamines or motor performance to proven human ID prevention."
    },
    {
      "subclaim_id": "SC2",
      "pitfall": "11. Intervention specificity assumed rather than demonstrated",
      "where": "Separate Phe add-back, diet composition and genetic repair; downstream biochemical mechanisms remain incomplete."
    },
    {
      "subclaim_id": "SC2",
      "pitfall": "Outcome-defined susceptibility, related to pitfall 20",
      "where": "The protected untreated sisters are not excluded after observing their IQ."
    },
    {
      "subclaim_id": "SC3",
      "pitfall": "Prevention confused with reversibility",
      "where": "SC3 is typed prevention. Improvement after late treatment does not establish reversal of established ID."
    },
    {
      "subclaim_id": "SC1/SC2/SC3",
      "pitfall": "18. Causal tallies that do not survive audit",
      "where": "US programme follow-up, overlapping registries, adult endpoints and mouse motor tasks retain their actual identities."
    },
    {
      "subclaim_id": "SC2",
      "pitfall": "9. Replication confused with reproduction",
      "where": "The brain-Phe explanation of protected cases rests on Möller 1998 [7] and Weglage 2001 [22], from the same group; the independent 2026 report [8] calls it unconfirmed."
    },
    {
      "subclaim_id": "SC2",
      "pitfall": "13. Therapeutic effect misread as mechanistic proof",
      "where": "R2 treated Phe-lowering drug approval as causal confirmation of Phe → ID; those trials measured Phe, not cognition [24,25]."
    },
    {
      "subclaim_id": "R2 decomposition",
      "pitfall": "10. Mechanism conflation (inverse form)",
      "where": "R2 added a downstream-mechanism subclaim (Ζ) that its own weakest-link alternative let gate a claim that asserts no downstream pathway."
    },
    {
      "subclaim_id": "SC2",
      "pitfall": "22. Scope fitted to the result — checked, not triggered",
      "where": "Protected untreated people are kept in scope; Θ is assigned with them counted as exceptions, not reclassified as non-susceptible."
    }
  ],
  "causal_tally_audit": {
    "tally_claimed_by_document": 7,
    "tally_after_audit": 9,
    "items_rejected": [
      "[3,5,6,8,15] are observational analyses, not new pivotal interventions.",
      "[7] measures intermediate brain Phe; [10] has a noninferior primary endpoint; [11] narrows a rival and is not a positive Phe-prevention experiment.",
      "[5] follows the programme of [4]; not a second independent experiment.",
      "Pass-02: R2 claimed 5 decisive perturbations (Bickel, Lenke & Levy, Pietz, sapropterin, pegvaliase); sapropterin [24] and pegvaliase are Phe-endpoint trials (cap 4) and are not decisive for SC2/SC3; Pietz [23] is decisive for brain handling (M2) only.",
      "[25] is a randomized perturbation with a null functional secondary result: it does not cross a threshold (clause 5).",
      "[19,20,21,22,26] are pooled, case-series, observational, physiological or review evidence."
    ],
    "breakdown": "Eleven records are flagged decisive, representing ten studies: [1,2,4,9,12,13,14], the maternal-PKU survey [16], the Maternal PKU Collaborative Study [17,18] (one study, two reports, counted once) and Pietz [23]. Pietz bears on the brain-handling submechanism only, so the audited tally for SC2/SC3 is nine studies. Only [2] and the maternal studies test the intellectual outcome in humans directly."
  },
  "steelman": {
    "case_one_rung_higher": "Ω: necessity and sufficiency are close to demonstrated at population scale. Removing the exposure early prevents the severe phenotype (sibling natural experiment [2], register dose-response on timing and control [3]); adding it back provokes deterioration [1,9]; and exposure without offspring PAH deficiency injures the developing brain in proportion to the timing of maternal control [16,18,27]. Grading A and blind run R2 both argued Ω for the upstream subclaim, and R2 argued the whole claim approaches Ω: rejecting it would require disregarding seven decades of clinical genetics and newborn screening.",
    "case_one_rung_lower": "Η (grading B and pass-01): similar severe biochemistry and identical genotypes coexist with discordant intellectual outcomes [2,8,21]; the candidate explanation (brain Phe handling) rests on one small outcome-selected study and a same-group follow-up whose IQ correlations only approached significance [7,22]; early-treated cohorts retain average deficits [3,5]; the one randomized pharmacological test with a functional readout was null at 8 weeks [25]. On a strict reading the unexplained exception sits inside the causal subclaim and Θ overstates.",
    "which_rejected": "Both rejected; Θ held for SC2 and the aggregate.",
    "blocking_cap_threshold_or_missing_experiment": "Ω is blocked by the Ω threshold ('Necessity AND sufficiency demonstrated ... no disqualifying contradictory data') and a named missing experiment: no study has prospectively predicted which untreated or poorly controlled patients are protected, so sufficiency across the claimed scope is not deterministic [2,8,20,21], and the downstream injury has no necessity/sufficiency account. Η is rejected because the Θ threshold ('minimal unresolved exceptions') is met: the residual deficit is accounted for by timing and control [3,5]; the protected phenotype is rare [8,20] and its members often still show Phe-attributable signs [2,8,20], so it is an exception to penetrance of the disability threshold, not to the causal effect; the null adult trial [25] tests an acute adult endpoint, not developmental ID."
  },
  "final_score": {
    "hsef_level": "Θ",
    "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions",
    "confidence": "High",
    "confidence_rationale": "Historical human developmental evidence, specific exposure challenges, longitudinal replication and controlled/genetically targeted models converge. Confidence describes reproducibility of the causal pattern, not GRADE certainty for every effect size or precision of the Η/Θ boundary. Pass-02 adds maternal-PKU and meta-analytic replication; unchanged band.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "SC1 Θ, SC2 Θ and SC3 Θ yield Θ by the preregistered weakest-link rule. Phe accumulation predicts untreated natural history, early-treatment rescue, dose-response on timing and control, and maternal-exposure injury in offspring without PAH deficiency. The rare protected untreated phenotype is unexplained and blocks Ω.",
    "merge_note": "Three independent gradings: A Θ, B Η, R2 (blind) Θ. Pass-01 posted Η; pass-02 raises SC2 and the aggregate to Θ and records B's and pass-01's Η case in full."
  },
  "role_of_mechanism": {
    "classification": "primary driver",
    "derivation_step_matched": "3",
    "derivation": "Developmental exposure control prevents the severe trajectory; specific added Phe can provoke functional deterioration; metabolic/genetic control changes the phenotype. Phe exposure is an upstream, outcome-limiting input in the PAH pathway, not merely a downstream marker. Rate-limiting is a causal interpretation, not a measured kinetic constant or universal penetrance claim. Pass-02: maternal exposure injuring offspring without PAH deficiency [16,18,27] adds an engagement-initiates test; dose-response on timing and control [3,18,19] supports rate-limiting.",
    "tournament_used_as_tiebreaker": false,
    "note": "No causal claim about every intellectual disability or every PAH variant is added."
  },
  "extended_scoring_MSD": {
    "momentum": {
      "value": "Mechanistic only",
      "artifact": "2026 native-allele correction with brain/motor outcomes [14], and 2026 discordant-sibling investigations [8].",
      "justification": "Nearest permitted label for active work refining mechanism and treatment. No named pending experiment resolving broad Θ penetrance was identified; the vocabulary fits a mature prevention field poorly. No exhaustive activity census.",
      "pass_02_note": "Blind run R2 assigned 'Decisive work underway' on liver-directed gene-therapy programmes. Registry status checked on ClinicalTrials.gov 2026-09-27: HMI-102 phase 1/2 (NCT03952156) terminated; BMN 307 (NCT04480567) active, not recruiting. Both use Phe endpoints and could not cross Ω for this claim. R2's value not adopted."
    },
    "stability": {
      "value": "Stable",
      "trigger": "No pending result was identified that would move the level. A prospective test of protection modifiers [7,21,22] would raise it toward Ω if positive; pass-02 did not identify one in progress.",
      "justification": "Current exceptions constrain deterministic/predictive breadth rather than establishing reverse causation."
    },
    "divergence": {
      "implied_level": "Θ",
      "implied_level_basis": "Field framing: a Lancet seminar states that untreated classic PKU results in profound and irreversible mental disability and that diet begun very soon after birth prevents most neuropsychological complications [26]; a 2026 primary report states there 'seems little doubt that disability results from the very high concentration of phenylalanine' and that early diet results in essentially normal development, while calling protected untreated cases very rare [8]. That is high predictive accuracy with acknowledged minor exceptions (Θ), not deterministic necessity-and-sufficiency (Ω).",
      "assessed_level": "Θ",
      "gap_in_rungs": 0,
      "value": "Aligned",
      "justification": "Field framing implies Θ; assessed Θ; gap 0, Aligned. The prior edition's 'reviewer-mapped implied Η' took the implied level from the reviewer's own assessment; recomputed against the posted Η it would have read +1, Mild overstatement."
    },
    "calibration_note": "M/S/D are assigned after the causal score and do not alter it."
  },
  "change_record": {
    "applies": true,
    "prior_level": "Η",
    "prior_confidence": "High",
    "prior_source": "Posted edition of 2026-09-27 (merge of grading A Θ and grading B Η, redteam pass-01), archived at sources/prior_posted_edition/, SHA-256 of scorecard 889325f4…",
    "derived_before_consulting_prior": true,
    "derivation_note": "An independent evidence view (SC2 Θ, aggregate Θ) was written after red-teaming R2 and before opening the prior edition, PROCESS_prior.md, pass-01 or grading B's protocol (PROCESS.md §3).",
    "new_level": "Θ",
    "direction": "raised",
    "what_moved_it": "SC2 Η → Θ under the Θ threshold 'High predictive accuracy with minimal unresolved exceptions'. (1) The posted blocker (residual deficit in early-treated cohorts not partitioned from a Phe-independent term) is met by source [3], already in the ledger: 46 best-treated children at mean IQ 112.6, matching the regression estimate and revised norms, with the authors attributing the residual to incomplete metabolic control; [5] shows no deficits except arithmetic with sustained control. (2) Grading B's blocker (protected untreated phenotype) is a real but minimal exception: very rare [8,20], its members often still Phe-marked [2,8,20]; it blocks Ω. (3) The maternal-PKU natural experiment [16,17,18,27], invoked but unsourced in the prior edition, adds exposure-without-genotype evidence. Weakest-link rule unchanged; aggregate Θ.",
    "divergence_from_other_reviewers": "Agrees with grading A (Θ) and blind run R2 (Θ) on the letter; disagrees with grading B (Η) and pass-01 (Η) on SC2 and states why. Disagrees with R2's route — scope-matched rule, five-subclaim decomposition, a contradicted concordance figure, and a pharmacological line capped at Γ — while agreeing with its letter. Readings are not evidence: the move rests on the sources named above, not on a vote."
  },
  "proposed_decisive_experiments": [
    {
      "name": "Independent explanation and prediction of protected untreated phenotypes",
      "experiment": "Study independently ascertained archival/prescreening cases with verified PAH deficiency, exposure history, brain Phe where feasible, genomic modifiers and both intellectual and adaptive-function outcomes; use a separate validation sample. Controlled developmental animal studies can separate timing, Phe and nutrition without withholding effective infant care.",
      "readout": "A prediction that distinguishes severe intellectual disability from preserved function before seeing validation outcomes, plus phenotype-relevant selective rescue.",
      "critical_control": "Do not recruit only by favorable outcome and call the resulting marker prospectively validated; measure baseline exposure and other causes. Do not treat blood or motor normalization as the intellectual endpoint.",
      "falsifying_result": "Repeated failure of the prespecified modifier/exposure prediction, or failure of selective early Phe lowering to prevent injury in a controlled relevant setting despite adequate nutrition.",
      "supporting_result": "Replicated outcome prediction and mechanistically selective prevention in independently defined contexts; this would support Ω-level coverage of the exception."
    }
  ],
  "knowledge_gaps": [
    {
      "name": "Protected untreated individuals",
      "statement": "Why similar severe biochemical and genetic findings can coexist with different intellectual outcomes.",
      "relevance": "Unresolved within-scope exception; blocks Ω (pass-02); not removed by retrospective susceptibility."
    },
    {
      "name": "Downstream injury mechanisms",
      "statement": "Relative necessity of brain amino-acid competition, neurotransmitter changes and other processes.",
      "relevance": "Prevention of clinical disease does not establish each molecular step."
    },
    {
      "name": "Residual effects and lifetime scope",
      "statement": "Which residual cognitive deficits reflect early exposure, ongoing adult exposure, nutrition or other factors.",
      "relevance": "Distinct from the established early prevention of severe developmental disability."
    },
    {
      "name": "Mediation of maternal-PKU injury",
      "statement": "Whether fetal injury from maternal Phe runs through the same brain pathways as postnatal PKU.",
      "relevance": "Would link the exposure-without-genotype evidence to the postnatal mechanism; does not affect the causal letter."
    }
  ],
  "review_metadata": {
    "review_date": "2026-09-27",
    "reviewer": "Inputs graded by: A — Codex (schema 5.3); B — Codex (schema 5.2 reference edition); C (R2) — Abacus AI Agent (blind run, self-described HSEF v5.3). Pass-01 synthesis: Claude (Anthropic). Red-team synthesis: Claude (Anthropic), independent model, 2026-09-27.",
    "created_at_utc": "2026-09-27T07:01:50+00:00",
    "evidence_base_note": "Targeted primary-literature review, including a 2026 update. Primary abstracts and status metadata read for all 15 reports; full Bickel paper and Demirbas article read. Not a systematic review or full-text-complete risk-of-bias audit. Pass-02 re-resolved all 15 prior ledger records and all 17 R2 records in PubMed, read full text of [1], [8], [23] (partial) and [25] (partial), and added 12 records (16–27).",
    "literature_tools_available": true,
    "literature_tools_note": "Life Sciences Literature Entrez search and fetch succeeded. PMC metadata lookup returned no current record for an older article; Europe PMC abstracts/full text and web-accessible original records supplemented access. Citation-context counts were not obtained. Pass-02: PubMed E-utilities (metadata, abstracts, PMC full text), Crossref (Følling DOI), ClinicalTrials.gov registry, publisher open-access pages. Europe PMC REST returned HTTP 429 (rate limit) and was not retried; erratum/retraction status was checked instead by PubMed publication-type searches.",
    "skill_version": "HSEF v5.4 · schema 5.4 · validator 2.4 · authoring standard 1.5",
    "validator_run": "pass",
    "validator_warnings_addressed": "See final/validation.txt. Disclosed WARNs: v5.calibration (this edition is not blind; reason recorded) and v5.calibration (band author had seen grading B, which forms this edition's body). Both are correct states, disclosed in Reviewer notes.",
    "archive_sha256": "30B23AD4C21209AFE1E683896439675995DAA85BAC10BACE71566777787E01BC",
    "registration_note": "Scope and weakest-link aggregation recorded after initial orientation searches but before grades; no false claim of preregistration before literature exposure.",
    "protocol_sha256": "e341ba10665aca848deffe7483fcf9b6706f25e5419fada8987182244910c0d4",
    "supplementary_validation": {
      "checker": "pah-pku-reference-checks.py",
      "passed": true,
      "negative_fixtures_rejected": 13,
      "exact_framework_quotes_checked": true,
      "archive_hash_unchanged": true,
      "target_commitment_verified": true,
      "grader_packet_excludes_target_and_prior_review": true
    },
    "redteam_synthesis": "red-team synthesis: Claude (Anthropic), independent model, 2026-09-27 (pass-02)",
    "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible."
  },
  "is_calibration_entry": {
    "value": true,
    "entry_role": "unblinded reference case",
    "blind_graded": false,
    "completed_blinded_calibration": false,
    "expected_band_sealed_at": "C:\\Users\\mjhen\\Documents\\Codex\\2026-09-26\\new-chat\\outputs\\pah-pku-calibration\\coordinator\\expected-band.json",
    "target_sha256": "fdfb4e7f7f2f28ab75a37c1f5fb4f8bbd730492c74fe90a5989a6a09d27e802f",
    "target_authorship": "Grading B's author (the unblinded reference author); not independent adjudication. Committed 2026-09-27T07:01:50Z.",
    "target_created_before_current_review": false,
    "target_created_note": "Retained from the prior edition: false relative to grading B, which forms this edition's body (the band was written after B's grading). The band was committed before R2 was frozen and before pass-02.",
    "target_author_saw_review": true,
    "target_author_note": "True for this edition: grading B is this edition's body. False for blind run R2, which did not exist when the band was committed.",
    "future_run_status": "executed",
    "unblinded_reason": "This edition is a red-team synthesis built with the prior edition and both unblinded gradings in view; it cannot be a blind grading. One separate blind run (R2) was executed and compared after freezing; see blind_run_record.",
    "blind_run_record": {
      "run_id": "R2",
      "grader_identity": "Abacus AI Agent (R2)",
      "artifact": "sources/C_R2_blind_run/pah-pku-scorecard.json + pah-pku-review.md",
      "frozen_by": "red team, 2026-09-27 (calibration_run/freeze-record-R2.json; frozen_at_utc 2026-09-28T01:37:04Z)",
      "scorecard_sha256": "ac8c19913a4272081f12c9ca624f5530794d36b1378bc858d0ba2e348f7b0b8d",
      "review_sha256": "00a6bb158e51558c9b68ad1316eee61735343b55b5640e2115b3361f1c38f59b",
      "observed_level": "Θ",
      "expected_band": [
        "Η",
        "Θ"
      ],
      "in_band": true,
      "commitment_verified": true,
      "isolation_account": "Coordinator's isolation account not on file",
      "independent_blinding_verification": false,
      "r2_conformance": "Fails validator 2.4 (4 FAIL, 3 WARN): two unverified numeric claims and gate_passed true with four unverified claims; 8 of 17 ledger PMIDs resolve to unrelated papers; one load-bearing figure contradicted.",
      "packet_scope_note": "R2 used schema-5.3 fields (entry_role, completed_blinded_calibration, access_depth, study_id, scope_qualifiers) that are absent from the grader packet (SKILL v5.0, template 5.2), so the grader worked with materials beyond the packet. The packet contains no PKU-specific content and no band, but it identifies the case as a calibration case and ships a validator that FAILs any calibration entry graded below Η.",
      "band_discrimination_note": "The sealed band spans Η–Θ and covers both earlier disagreeing gradings, the prior posted level and this level; agreement with it cannot discriminate between them.",
      "counts_as_completed_calibration": "undecided — referred to the owner",
      "redteam_recommendation": "Record R2 as 'executed, non-conforming': report the band comparison as a weak datum on reachability, not as a completed blinded calibration, because the isolation account is missing, the run exceeded its packet, the band cannot discriminate Η from Θ, and the artifact would not pass the v5.4 publication gate. Run a fresh blind grading from a v5.4 packet with the Η floor removed from the grader's validator, a documented isolation account, and a band set by someone who has not graded the hypothesis."
    }
  },
  "upper_ladder_check": {
    "final_level_below_zeta": false,
    "equivalents_considered": [
      {
        "kind": "human_natural_experiment",
        "available": true,
        "why_not_sufficient": "Sufficient for causal developmental support; not deterministic prediction for all biochemical phenotypes."
      },
      {
        "kind": "specific_therapeutic_and_exposure_perturbation",
        "available": true,
        "why_not_sufficient": "Adult and animal endpoints remain supporting rather than direct human ID prevention."
      }
    ],
    "convergence_present": true,
    "cap_reapplied_to_convergent_set": false
  },
  "provenance_header": {
    "sources_total": 27,
    "claims_total": 35,
    "claims_verified": 35,
    "claims_unverified": 0,
    "claims_contradicted": 0,
    "tier_a_sources": 25,
    "generated_by": "Posted edition 2026-09-27 (A+B merge, pass-01) revised by red-team pass-02 (Claude, Anthropic); HSEF v5.4, schema 5.4, validator 2.4",
    "gate_passed": true
  },
  "claims": [
    {
      "id": "C1",
      "text": "PAH loss of function impairs phenylalanine-to-tyrosine conversion and permits phenylalanine accumulation; functional human findings and native-allele correction in mice support that biochemical link.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        8,
        14
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Mechanistic synthesis, not a claim that every PAH variant produces an identical untreated concentration.",
      "pass_02_recheck": "PubMed abstracts of [8] and [14] re-read 2026-09-27; [8] full text read."
    },
    {
      "id": "C2",
      "text": "Bickel and colleagues reported improvement during a low-phenylalanine diet and deterioration on phenylalanine add-back in one already impaired child; the first add-back was concealed from the mother.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        1
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Single case and short-term neurological/behavioral observations; not a demonstration of preventing or fully reversing intellectual disability.",
      "pass_02_recheck": "Full text (two-page scan, James Lind Library copy) read 2026-09-27: 'added to the hydrolysate without the mother's knowledge'."
    },
    {
      "id": "C3",
      "text": "Smith and Wolff compared 28 affected sibling pairs, including earlier-treated subsequently born siblings and late/untreated siblings; intellectual outcome favored early treatment.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        2
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Nonrandomized natural experiment. Ascertainment through an impaired index case, birth order and changes in care remain relevant.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C4",
      "text": "The same sibling report estimated that about one in six or seven untreated classical-PKU patients could have IQ above 70 while still showing intellectual impairment.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        2
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Historical cohort estimate, not a modern population penetrance rate; IQ alone is not the complete modern diagnostic definition of intellectual disability.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C5",
      "text": "The UK register analysis included 1,031 early-treated children, with 808 followed prospectively; later treatment and poorer phenylalanine control were associated with lower childhood IQ.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Dose/timing associations within a treated cohort are not randomized effect estimates; family and treatment factors may confound them.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C6",
      "text": "In that register, prolonged concentrations below 120 micromol/L were also associated with poorer IQ, and the later birth cohort remained about eight IQ points below revised norms.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Adequacy of nutrition matters. Prevention of severe disability does not mean complete normalization of every cognitive measure; this historical value is not a current target.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C7",
      "text": "The preliminary randomized diet-discontinuation report enrolled 115 children; adjusted IQ at eight years was 101 versus 98 (P=0.075), with significant reading and spelling differences favoring continuation.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        4
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Do not call the IQ comparison statistically significant or substitute school-test differences for incident intellectual disability.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C8",
      "text": "The later US collaborative report assessed 95 children at age 12; outcomes were related to treatment history, blood phenylalanine and parent IQ.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        5
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Same study programme as [4]. Achieved-control comparisons are observational, even though PubMed also indexes the programme as an RCT.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C9",
      "text": "Thirty-one untreated people with persistent phenylalanine concentrations of 360–600 micromol/L had mean IQ 103±15 versus 104±11 in controls.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        6
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "A severity-boundary cohort, not proof that every mild elevation is harmless or that historical treatment recommendations should be adopted today.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C10",
      "text": "A separate study of 82 children with concentrations below 900 micromol/L, including 24 untreated children, found lower average IQ and a phenylalanine–IQ association.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        15
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Its age, concentration range and recruitment differ from [6]; these cannot be treated as the same exposure population or pooled without further work.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C11",
      "text": "An MRS study of 11 PKU patients found lower brain phenylalanine in three untreated women with normal or near-normal intelligence despite high blood concentrations.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        7
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Small, outcome-selected physiological comparison; not a validated prospective susceptibility classifier.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C12",
      "text": "The 2026 report describes two untreated sisters with the same PAH variants, similar high blood phenylalanine and markedly different intellectual outcomes; the investigated factors did not establish an explanation.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        8
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Their reported full-scale IQs were 88 and 54. Brain phenylalanine was not measured, so a transport explanation was neither established nor excluded; early-life exposure was not continuously measured.",
      "pass_02_recheck": "PMC full text read 2026-09-27: WAIS-R full-scale IQ 88 (age 28) and 54 (age 31); genotype p.R261Q/p.W187X in both."
    },
    {
      "id": "C13",
      "text": "A double-blind crossover trial in nine treated adults found worse sustained attention and mood during phenylalanine supplementation.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        9
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Acute adult functional effect, not developmental intellectual-disability induction or prevention.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C14",
      "text": "A 2024 crossover trial in 30 early-treated adults found four weeks of higher phenylalanine intake noninferior to placebo for its primary working-memory-accuracy endpoint; sustained attention was an exception among secondary outcomes.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        10
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Retain the primary result. It does not establish developmental or lifelong safety, nor does it replicate a universal adult cognitive deficit.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C15",
      "text": "In a crossover study of 21 people with PKU, tyrosine supplementation raised plasma tyrosine without improving the measured neuropsychological performance.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        11
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Constrains this supplementation strategy; does not exclude every downstream role for tyrosine or neurotransmitters, especially during development.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C16",
      "text": "Dietary restriction or liver-directed gene therapy started in adult PKU mice improved monoamines and nesting behavior but did not correct their severe cognitive deficits.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        12
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Directly separates biochemical/behavioral reversibility from reversal of established cognitive injury; mouse findings are not human clinical effect sizes.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C17",
      "text": "In a controlled long-term mouse study, low-phenylalanine diets improved some functions, while a nutrient combination improved novel-object recognition even under high-phenylalanine conditions.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        13
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Some, not all, tasks improved. Nutrition can modify an animal endpoint without disproving phenylalanine causation or replacing early human treatment.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C18",
      "text": "Corrective editing of the native PAH P281L variant in humanized mice lowered plasma and cortical phenylalanine and improved motor abnormalities.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        14
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Genetically targeted rescue without wholesale dietary restriction; motor and biochemical outcomes are not demonstration of human intellectual-disability prevention.",
      "pass_02_recheck": "PubMed abstract re-read 2026-09-27."
    },
    {
      "id": "C19",
      "text": "Early phenylalanine control changes developmental outcomes despite the underlying PAH deficiency remaining; this argues against an unavoidable brain defect wholly independent of the metabolic exposure.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC2",
        "SC3"
      ],
      "source_ns": [
        1,
        2,
        3,
        5,
        14
      ],
      "verification": "verified",
      "verified_against": "Primary records specified in the source ledger; factual premises checked, synthesized causal judgments distinguished in the note.",
      "verified_on": "2026-09-27",
      "note": "Reviewer causal synthesis from convergent experiments and cohorts, not an assertion that the complete downstream molecular pathway is known.",
      "pass_02_recheck": "Synthesis; constituent records re-read 2026-09-27."
    },
    {
      "id": "C20",
      "text": "In the UK register, the 46 cohort-2 children with the most favourable treatment characteristics had a mean IQ of 112.6 after standardising for social class, similar to the regression estimate and to revised population norms; the authors attributed the residual deficit of early-treated children to the difficulties in fully controlling the metabolic abnormality.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Subgroup defined by treatment characteristics (start age, control), not by outcome; achieved control is still not randomized.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C21",
      "text": "In the US collaborative 12-year follow-up, children who kept blood Phe below 900 µmol/L beyond age 10 showed no test-score deficits except arithmetic, which declined between ages 6 and 12 in 90% of the children studied.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        5
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Same programme as [4]; observational achieved-control comparison.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C22",
      "text": "Lenke and Levy surveyed 524 pregnancies in 155 women; in untreated pregnancies, mental retardation, microcephaly and congenital heart disease in the offspring were greatly increased and correlated with maternal blood Phe, and 95% of mothers with blood Phe of 20 mg/dL or more had at least one mentally retarded child.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        16
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "The 92%/73% figures R2 attributed to this paper are not in the abstract; the full text was not accessible, so they are not used.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C23",
      "text": "The Maternal PKU International Study enrolled 382 women with hyperphenylalaninaemia (572 pregnancies); optimal birth outcomes occurred when maternal blood Phe of 120–360 µmol/L was achieved by 8–10 weeks' gestation and maintained, and pre- and periconceptional control significantly decreased offspring morbidity.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        17
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Same study as [18]. Historical targets are not presented as current advice.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C24",
      "text": "In the Maternal PKU Collaborative Study (253 children followed to age 4, 149 born to women with PKU), the offspring General Cognitive Index fell as weeks to maternal metabolic control increased (r = −0.58); offspring of women in control before pregnancy averaged 99 (SD 13), and 47% of offspring whose mothers lacked control by 20 weeks scored 2 SD below the norm.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        18
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Observational dose-timing; same study as [17].",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C25",
      "text": "A systematic literature review and meta-analysis of within-study correlations found a significant inverse relation between blood Phe and IQ in early-treated patients during the childhood critical period, and stated its aim as validating blood Phe as a predictive biomarker for treatment trials.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        19
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Tier B pooled analysis; its numeric estimates are recorded in redteam/claim-audit.md and not carried as evidence-card figures.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C26",
      "text": "An international search identified 16 living untreated or late-diagnosed PKU patients with near-normal intellectual outcome despite high Phe; they often had other neurological, psychological and behavioural problems.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        20
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Outcome-selected case series; frequency not estimable.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C27",
      "text": "In 42 families with untreated PKU, genotype-predicted PAH activity was associated with intellectual phenotype but with extensive overlap; siblings and unrelated individuals with the same genotype had very different intellectual phenotypes not explained by diet, and no modifier was found.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        21
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C28",
      "text": "In 15 patients with classic PKU, brain Phe differed widely at similar blood Phe; transport parameters correlated with white-matter abnormality, while their correlations with intelligence only approached significance.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        22
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Same research group as [7].",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C29",
      "text": "In six adult men with PKU (crossover), an oral Phe load raised brain Phe from about 250 to about 400 µmol/L with EEG slowing; with concurrent large-neutral-amino-acid supplementation, brain Phe influx was blocked and EEG slowing was absent.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        23
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract; JCI full text (subjects and results)",
      "verified_on": "2026-09-27",
      "note": "Resolves R2's unverified C7; bears on brain handling (M2), not on the developmental endpoint.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C30",
      "text": "In a phase III randomized trial in 89 patients, sapropterin lowered mean blood Phe by 236 µmol/L over 6 weeks versus a 3 µmol/L rise on placebo; the primary endpoint was blood Phe.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        24
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Resolves R2's unverified C8. Biomarker endpoint only.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C31",
      "text": "In the PRISM-2 randomized discontinuation trial, switching to placebo raised blood Phe within 8 weeks (least-squares mean change 949.8 and 664.8 µmol/L in the two placebo groups versus 26.5 µmol/L with continued pegvaliase), but secondary neuropsychiatric and mood endpoints showed no significant differences between groups; the authors suggested trial duration or tools may have been inadequate.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        25
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract; open-access full text (results, discussion)",
      "verified_on": "2026-09-27",
      "note": "R2's C9 figure ('50–70%') belongs to the open-label programme report (PMID 29653686: 51.1% at 12 and 68.7% at 24 months); it is not carried.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C32",
      "text": "A Lancet seminar states that untreated classic PKU results in profound and irreversible mental disability and that a Phe-restricted diet begun very soon after birth prevents most of the neuropsychological complications.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        26
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Tier B; field framing for the Divergence implied level only.",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C33",
      "text": "In the 2026 sister report, the intellectually normal untreated sister (full-scale IQ 88; verbal 108, performance 77) had white-matter reduction on MRI and increased deep tendon reflexes; the authors describe untreated people without intellectual disability as very rare and state there seems little doubt that disability results from the very high Phe concentration.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        8
      ],
      "verification": "verified",
      "verified_against": "PMC full text",
      "verified_on": "2026-09-27",
      "note": "",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C34",
      "text": "A mother with PKU had one PKU and one non-PKU child from untreated pregnancies; both were microcephalic and intellectually impaired (IQ below 50 and 54), and the authors concluded that residual liver PAH activity of a non-PKU fetus offers little or no protection.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        27
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "",
      "added_in": "redteam pass-02"
    },
    {
      "id": "C35",
      "text": "Early-treated register children lost roughly four IQ points for each four weeks' delay in starting treatment and for each 300 µmol/L rise in mean Phe during treatment.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "PubMed abstract",
      "verified_on": "2026-09-27",
      "note": "Dose-response within a treated cohort; observational.",
      "added_in": "redteam pass-02"
    }
  ],
  "citation_ledger": [
    {
      "n": 1,
      "citation": "BICKEL H, GERRARD J, HICKMANS EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;265(6790):812-813.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "13098090",
      "doi": "10.1016/s0140-6736(53)90473-5",
      "url": "https://pubmed.ncbi.nlm.nih.gov/13098090/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C2",
        "C19"
      ],
      "record_access": "Original two-page 1953 article read in a scanned primary-paper copy hosted by the James Lind Library; PubMed/Europe PMC metadata checked. PubMed has no abstract.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "additional_opened_url": "https://www.jameslindlibrary.org/wp-data/uploads/2016/06/Bickel_et_al_1953_-Lancet_Influence_-of_phenylalanine_-intake_on_-phenylketonuria.pdf",
      "study_id": "PMID_13098090",
      "access_depth": "full_text_complete",
      "access_note": "Two-page original read in full (James Lind Library scan) in pass-02; PubMed has no abstract.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 2,
      "citation": "Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. Lancet. 1974;2(7880):540-544.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "4140266",
      "doi": "10.1016/s0140-6736(74)91873-x",
      "url": "https://pubmed.ncbi.nlm.nih.gov/4140266/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C3",
        "C4",
        "C19"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "SMITH_WOLFF_1974_SIBLING_STUDY",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 3,
      "citation": "Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child. 1990;65(5):472-478.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "2357082",
      "doi": "10.1136/adc.65.5.472",
      "url": "https://pubmed.ncbi.nlm.nih.gov/2357082/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C5",
        "C6",
        "C19",
        "C20",
        "C35"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "research_program": "UK-PKU-Register",
      "cohort_overlap_note": "Same research programme; participant overlap was not exhaustively resolved. Do not count as separate modalities or sum sample sizes.",
      "study_id": "UK_PKU_REGISTER_1964_1980",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 4,
      "citation": "Koch R, Azen CG, Friedman EG, et al. Preliminary report on the effects of diet discontinuation in PKU. J Pediatr. 1982;100(6):870-875.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "7086586",
      "doi": "10.1016/s0022-3476(82)80503-9",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7086586/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C7"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "US-PKU-Collaborative-Study",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 5,
      "citation": "Azen CG, Koch R, Friedman EG, et al. Intellectual development in 12-year-old children treated for phenylketonuria. Am J Dis Child. 1991;145(1):35-39.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "1985428",
      "doi": "10.1001/archpedi.1991.02160010037012",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1985428/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C8",
        "C19",
        "C21"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [
        {
          "source": "MED",
          "id": "1985426",
          "reference": "Am J Dis Child. 1991 Jan;145(1):33. doi: 10.1001/archpedi.1991.02160010035010",
          "type": "Comment in",
          "orderIn": 1
        }
      ],
      "study_id": "US-PKU-Collaborative-Study",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained.",
      "pass_02_note": "study_id harmonised with [4] (same US Collaborative Study programme; prior edition used two different strings)."
    },
    {
      "n": 6,
      "citation": "Weglage J, Pietsch M, Feldmann R, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res. 2001;49(4):532-536.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "11264437",
      "doi": "10.1203/00006450-200104000-00015",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11264437/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C9"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "PMID_11264437",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 7,
      "citation": "Möller HE, Weglage J, Wiedermann D, et al. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18(11):1184-1191.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "9809507",
      "doi": "10.1097/00004647-199811000-00004",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9809507/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C11"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "PMID_9809507",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 8,
      "citation": "Demirbas D, Waisbren SE, Bodamer O, et al. Two adult sisters with untreated phenylketonuria: Strikingly discordant clinical phenotype. Mol Genet Metab Rep. 2026;46:101304.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "41853686",
      "doi": "10.1016/j.ymgmr.2026.101304",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41853686/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C1",
        "C12",
        "C33"
      ],
      "record_access": "Complete original article text retrieved and read through Europe PMC fullTextXML, plus indexed primary abstract and metadata; no inference from the failed PubMed/PMC browser pages.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "additional_opened_url": "https://europepmc.org/articles/PMC12991959",
      "study_id": "PMID_41853686",
      "access_depth": "full_text_complete",
      "access_note": "PMC full text read in pass-02 (case reports, psychological assessments, discussion).",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 9,
      "citation": "ten Hoedt AE, de Sonneville LM, Francois B, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011;34(1):165-171.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "21153445",
      "doi": "10.1007/s10545-010-9253-9",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21153445/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C13"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "NTR1056",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 10,
      "citation": "Trepp R, Muri R, Maissen-Abgottspon S, et al. Cognition after a 4-week high phenylalanine intake in adults with phenylketonuria - a randomized controlled trial. Am J Clin Nutr. 2024;119(4):908-916.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "38569786",
      "doi": "10.1016/j.ajcnut.2023.11.007",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38569786/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C14"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [
        {
          "source": "MED",
          "id": "38296030",
          "reference": "Am J Clin Nutr. 2024 Apr;119(4):870-871. doi: 10.1016/j.ajcnut.2024.01.023",
          "type": "Comment in",
          "orderIn": 1
        }
      ],
      "study_id": "NCT03788343",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 11,
      "citation": "Smith ML, Hanley WB, Clarke JT, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch Dis Child. 1998;78(2):116-121.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "9579151",
      "doi": "10.1136/adc.78.2.116",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9579151/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C15"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "SMITH_ML_1998_TYROSINE",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 12,
      "citation": "Winn SR, Scherer T, Thöny B, et al. Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice. Mol Genet Metab. 2018;123(1):6-20.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "29331172",
      "doi": "10.1016/j.ymgme.2017.10.009",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29331172/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C16"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "WINN_2018_ADULT_PAHENU2",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 13,
      "citation": "Bruinenberg VM, van Vliet D, van der Goot E, et al. Long-term dietary intervention with low Phe and/or a specific nutrient combination improve certain aspects of brain functioning in phenylketonuria (PKU). PLoS One. 2019;14(3):e0213391.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "30875376",
      "doi": "10.1371/journal.pone.0213391",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30875376/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C17"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "PMID_30875376",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 14,
      "citation": "Gautier MK, King K, Han Y, et al. In vivo adenine base editing rescues brain biochemistry and improves motor deficits in a common phenylketonuria variant. Mol Ther Adv. 2026;34(2):201760.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "42290942",
      "doi": "10.1016/j.omta.2026.201760",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42290942/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C1",
        "C18",
        "C19"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "study_id": "PMID_42290942",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 15,
      "citation": "Costello PM, Beasley MG, Tillotson SL, et al. Intelligence in mild atypical phenylketonuria. Eur J Pediatr. 1994;153(4):260-263.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "8194559",
      "doi": "10.1007/bf01954515",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8194559/",
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C10"
      ],
      "record_access": "Original-paper abstract and bibliographic/status metadata read in Europe PMC indexed records; Entrez and web records cross-checked where available.",
      "status_scope": "No retraction, correction or concern in the inspected indexed fields; linked commentaries are not correction notices.",
      "linked_commentaries": [],
      "research_program": "UK-PKU-Register",
      "cohort_overlap_note": "Same research programme; participant overlap was not exhaustively resolved. Do not count as separate modalities or sum sample sizes.",
      "study_id": "PMID_8194559",
      "access_depth": "abstract_metadata",
      "access_note": "PubMed abstract and metadata re-read in pass-02; full text not audited.",
      "pass_02_identifier_check": "PMID resolved 2026-09-27; title, first author, journal, year, volume, pages and DOI match the record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions in PKU/phenylalanine literature (2026-09-27); none attached to this record. Earlier Europe PMC inspection by grading B retained."
    },
    {
      "n": 16,
      "citation": "Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med. 1980;303(21):1202-1208.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "7421947",
      "doi": "10.1056/NEJM198011203032104",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7421947/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C22"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "LENKE_LEVY_1980_SURVEY",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only; publisher full text returned 403.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 17,
      "citation": "Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics. 2003;112(6 Pt 2):1523-1529.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "14654658",
      "doi": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/14654658/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C23"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "MPKUCS",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only. No DOI in the PubMed record.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 18,
      "citation": "Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA. 2000;283(6):756-762.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "10683054",
      "doi": "10.1001/jama.283.6.756",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10683054/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C24"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "MPKUCS",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 19,
      "citation": "Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1-2):63-70.",
      "tier": "B",
      "kind": "meta_analysis",
      "pmid": "17591452",
      "doi": "10.1016/j.ymgme.2007.05.006",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17591452/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C25"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "WAISBREN_2007_META",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 20,
      "citation": "van Vliet D, van Wegberg AMJ, Ahring K, et al. Untreated PKU patients without intellectual disability: what do they teach us? Nutrients. 2019;11(11):2572.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "31731404",
      "doi": "10.3390/nu11112572",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31731404/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C26"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "VAN_VLIET_2019_SERIES",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only (PMC6893397 available, not audited).",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 21,
      "citation": "Ramus SJ, Forrest SM, Pitt DD, Cotton RG. Genotype and intellectual phenotype in untreated phenylketonuria patients. Pediatr Res. 1999;45(4 Pt 1):474-481.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "10203137",
      "doi": "10.1203/00006450-199904010-00004",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10203137/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C27"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "RAMUS_1999_VICTORIA",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 22,
      "citation": "Weglage J, Wiedermann D, Denecke J, et al. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol. 2001;50(4):463-467.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "11601498",
      "doi": "10.1002/ana.1226",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11601498/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C28"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "WEGLAGE_2001_BBB",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only. Same group as [7]; patient overlap not resolved.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 23,
      "citation": "Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8):1169-1178.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "10207169",
      "doi": "10.1172/JCI5017",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10207169/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C29"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "PIETZ_1999_LNAA",
      "access_depth": "full_text_partial",
      "access_note": "Abstract plus JCI full text: subjects/methods (six men, crossover, 100 mg/kg Phe load) and results (brain Phe, EEG). Discussion not audited.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02",
      "additional_opened_url": "https://www.jci.org/articles/view/5017"
    },
    {
      "n": 24,
      "citation": "Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370(9586):504-510.",
      "tier": "A",
      "kind": "rct",
      "pmid": "17693179",
      "doi": "10.1016/S0140-6736(07)61234-3",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17693179/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C30"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "NCT00104247",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 25,
      "citation": "Harding CO, Amato RS, Stuy M, et al. Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab. 2018;124(1):20-26.",
      "tier": "A",
      "kind": "rct",
      "pmid": "29628378",
      "doi": "10.1016/j.ymgme.2018.03.003",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29628378/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C31"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "PRISM",
      "access_depth": "full_text_partial",
      "access_note": "Abstract plus open-access full text: results and discussion on secondary neuropsychiatric endpoints.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02",
      "additional_opened_url": "https://www.sciencedirect.com/science/article/pii/S1096719218300209"
    },
    {
      "n": 26,
      "citation": "Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417-1427.",
      "tier": "B",
      "kind": "review",
      "pmid": "20971365",
      "doi": "10.1016/S0140-6736(10)60961-0",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20971365/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C32"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "BLAU_2010_SEMINAR",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only; used for field framing.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    },
    {
      "n": 27,
      "citation": "Levy HL, Lobbregt D, Sansaricq C, Snyderman SE. Comparison of phenylketonuric and nonphenylketonuric sibs from untreated pregnancies in a mother with phenylketonuria. Am J Med Genet. 1992;44(4):439-442.",
      "tier": "A",
      "kind": "primary_research",
      "pmid": "1442884",
      "doi": "10.1002/ajmg.1320440411",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1442884/",
      "status_flags": [
        "none_found"
      ],
      "carries_claims": [
        "C34"
      ],
      "opened": true,
      "opened_on": "2026-09-27",
      "status_checked_on": "2026-09-27",
      "study_id": "LEVY_1992_SIBS",
      "access_depth": "abstract_metadata",
      "access_note": "Abstract only.",
      "status_check_method": "PubMed record plus PubMed publication-type searches for errata, expressions of concern and retractions (2026-09-27); none attached. Europe PMC check not completed (HTTP 429).",
      "added_in": "redteam pass-02"
    }
  ],
  "independence_basis": {
    "required": true,
    "lines": [
      {
        "label": "Human developmental diet intervention and natural experiments",
        "sources": [
          2,
          3,
          4,
          5,
          15,
          19
        ],
        "excludes_error": "Affected-sibling and treatment-timing contrasts challenge an inevitable genotype-only brain outcome. Prospective outcomes reduce retrospective outcome recall; family, birth-order and adherence confounding remain.",
        "endpoint_scope": "Childhood intellectual/achievement outcomes; [2] directly compares early treatment against late/absent treatment.",
        "qualifies_as_independent_causal_modality": true,
        "direct_human_ID_prevention_line": true,
        "limits": "Nonrandomized neonatal comparisons; later randomization and achieved control are distinguished. All such cohorts are one nutritional modality. [19] pools overlapping cohorts and is counted within this line only."
      },
      {
        "label": "Specific phenylalanine add-back with the treatment/care context held more nearly fixed",
        "sources": [
          1,
          9,
          10
        ],
        "excludes_error": "Isolating added Phe, with blinded crossover in adults, addresses nonspecific nutritional benefit, extra attention and secular changes that could mislead developmental cohorts.",
        "endpoint_scope": "Short-term neurological behavior, mood, attention and working memory; not induced developmental ID.",
        "qualifies_as_independent_causal_modality": true,
        "direct_human_ID_prevention_line": false,
        "limits": "Small early challenge and brief adult trials; the 2024 primary outcome was noninferior. Loading doses and life stage limit extrapolation."
      },
      {
        "label": "Controlled PAH-deficient animal experiments, including dietary manipulation and native-allele repair",
        "sources": [
          12,
          13,
          14
        ],
        "excludes_error": "Experimental control and targeted genetic correction address family/adherence confounding and diet-only cointerventions. Human clinical findings supply the species-relevance check.",
        "endpoint_scope": "Metabolism, neurotransmitters, learning tasks, nesting and motor behavior; not a human ID diagnosis.",
        "qualifies_as_independent_causal_modality": true,
        "direct_human_ID_prevention_line": false,
        "limits": "Count this animal family as one line despite multiple methods/backgrounds. Adult rescue does not restore all learning deficits; motor rescue is not intellectual rescue."
      },
      {
        "label": "Maternal-PKU natural experiment: exposure without offspring PAH deficiency",
        "sources": [
          16,
          17,
          18,
          27
        ],
        "excludes_error": "A PAH-genotype-intrinsic brain defect, and confounding by the affected child's own diet, care or adherence: the exposed offspring are ordinarily not PAH-deficient [27], yet injury rises with maternal Phe and with delay to maternal control [16,18]. Its ascertainment and adherence errors (maternal case-finding, maternal diet control) differ from those of the sibling and register cohorts.",
        "endpoint_scope": "Offspring intellectual/developmental outcome, microcephaly, congenital anomalies.",
        "qualifies_as_independent_causal_modality": true,
        "direct_human_ID_prevention_line": true,
        "limits": "Retrospective survey [16] plus one prospective study reported twice [17,18]; achieved maternal control is not randomized; [27] is a single family. Fetal exposure differs in timing from postnatal PKU.",
        "added_in": "redteam pass-02"
      },
      {
        "label": "Human PAH functional and genotype-discordance observations",
        "sources": [
          8,
          20,
          21
        ],
        "excludes_error": "Links the biochemical defect to the specified inherited disorder while exposing that genotype and blood Phe do not uniquely predict cognition.",
        "endpoint_scope": "Existing intellectual phenotype in untreated patients: two siblings [8], an international series [20], 42 families [21].",
        "qualifies_as_independent_causal_modality": false,
        "direct_human_ID_prevention_line": false,
        "limits": "Corroborating/boundary evidence, not an additional controlled developmental causal experiment."
      },
      {
        "label": "Brain-versus-blood phenylalanine physiology",
        "sources": [
          7,
          22,
          23
        ],
        "excludes_error": "Direct brain measurements address the assumption that blood Phe fully specifies cerebral exposure.",
        "endpoint_scope": "MRS and transport response, with cognition assessed in outcome-selected individuals.",
        "qualifies_as_independent_causal_modality": false,
        "direct_human_ID_prevention_line": false,
        "limits": "Small selected study; no validated susceptibility classifier and no direct preventive ID endpoint. [22] is from the same group as [7]; [23] is a six-person acute loading study."
      },
      {
        "label": "Pharmacological Phe lowering (blind run R2's proposed line) — not qualifying",
        "sources": [
          24,
          25
        ],
        "excludes_error": "Would exclude dietary-compliance and care confounding if a functional endpoint moved; here the primary endpoints are blood Phe [24,25] and the randomized functional secondary endpoints were null at 8 weeks [25].",
        "endpoint_scope": "Blood Phe; adult short-term neuropsychiatric scales.",
        "qualifies_as_independent_causal_modality": false,
        "direct_human_ID_prevention_line": false,
        "limits": "Cap 4 binds the inference from this class alone. Disclosed so the reader can see why R2's fourth line is not counted.",
        "added_in": "redteam pass-02"
      }
    ],
    "listed_line_count": 7,
    "qualifying_causal_modality_count": 4,
    "direct_human_ID_prevention_line_count": 2,
    "shared_failure_mode_checked": true,
    "note": "Seven rows disclose supportive, boundary and rejected evidence; four are qualifying modalities (developmental diet/natural experiments; specific add-back; controlled animal experiments; maternal-PKU exposure without offspring PAH deficiency). No single systematic error — family ascertainment, adherence, nutrition, species, or offspring genotype — could produce all four. Reports of one study share a study_id and sit in one line."
  },
  "headline_finding": "PAH-related phenylalanine accumulation is an established cause of the intellectual disability of untreated PKU, and early dietary control prevents its severe phenotype; the integrated claim is Θ with High confidence.",
  "headline_gap": "A rare minority of untreated people with severe biochemical disease escape intellectual disability, and no one can yet predict or explain who; early prevention does not imply late reversal.",
  "checked_sources": [
    {
      "tool": "Life Sciences Literature Entrez",
      "outcome": "Search and primary-record fetch succeeded; compact previews supplemented by full primary abstracts."
    },
    {
      "tool": "Life Sciences Literature PMC metadata",
      "identifier": "PMC1377241",
      "outcome": "No current dataset metadata; this is not evidence of article absence."
    },
    {
      "tool": "Primary article access",
      "outcome": "Bickel scan and Demirbas fullTextXML read; some PubMed/PMC web pages returned bot checks."
    },
    {
      "tool": "Guldberg 1998 primary record",
      "identifier": "PMID 9634518",
      "outcome": "Erratum detected; correction details not retrieved. Excluded from the load-bearing ledger rather than using allele-specific classifications unchecked."
    },
    {
      "tool": "ACMG guideline context",
      "identifier": "PMID 39630157; correction PMID 41511485",
      "outcome": "Guideline and correction identified. Historical cohort thresholds are not used as present clinical recommendations; guideline not counted as a primary causal experiment."
    },
    {
      "tool": "US Collaborative Study summary",
      "identifier": "PMID 8828605",
      "outcome": "Used to identify programme overlap. Not counted as an additional primary experiment or separate causal line."
    }
  ],
  "redteam_review": {
    "performed": true,
    "date": "2026-09-27",
    "reviewer": "Claude (Anthropic) — independent model, adversarial pass",
    "inputs_reviewed": [
      "grading A (schema 5.3)",
      "grading B (schema 5.2)",
      "both validation reports",
      "preregistered protocol",
      "calibration apparatus"
    ],
    "independent_verification": {
      "records_checked_against_PubMed": 5,
      "records_exact": 5,
      "method": "Shared ledger entries retrieved from PubMed and compared on title, journal, volume, pages and DOI."
    },
    "findings": [
      "Aggregates disagreed by one rung (Θ vs Η); traced to SC2 alone.",
      "Only 7 of 15 ledger sources were shared, so the difference may reflect source selection as much as adjudication. Neither package can distinguish these.",
      "Grading A asserted Ω at SC1, which does not bind under weakest-link.",
      "Grading A carried one ledger row with an empty PMID (Bickel 1953).",
      "Grading B lacked all schema 5.3 fields.",
      "Grading A declined calibration designation; B carried the full apparatus.",
      "The v5.3 additions caught no error in either package; they documented good practice rather than preventing a defect."
    ],
    "actions_taken": [
      "Adopted B's grading and calibration apparatus as base.",
      "Migrated to schema 5.3 using A's field work.",
      "Resolved SC2 explicitly, upward case written first.",
      "Recorded A's Ω at SC1 as documented dissent.",
      "Flagged the empty-PMID row."
    ],
    "residual_limitations": [
      "No blinded calibration run has been executed; both gradings were unblinded.",
      "The expected band was authored by a party who had seen prior discussion.",
      "The protocol states orientation searches preceded it, so registration was partial."
    ]
  },
  "redteam_review_pass_02": {
    "performed": true,
    "date": "2026-09-27",
    "reviewer": "Claude (Anthropic) — independent model, adversarial pass-02",
    "inputs_reviewed": [
      "blind run R2 (input C: md, json, docx, pdf) with baseline validator 2.4",
      "prior posted edition (A+B merge, pass-01) with baseline validator 2.4",
      "PROCESS_prior.md, redteam pass-01, grading B's protocol, grading A (for union reconciliation)",
      "calibration apparatus (copied to calibration_run/; original untouched)"
    ],
    "order_followed": "R2 red-teamed on its own merits → independent view written → prior edition read and reconciled → calibration comparison run last",
    "independent_verification": {
      "r2_ledger_rows_resolved": 17,
      "r2_rows_with_wrong_pmid": 8,
      "prior_ledger_rows_resolved": 15,
      "prior_rows_exact": 15,
      "rows_added": 12
    },
    "level_change": "Η → Θ (SC2 Η → Θ)",
    "full_record": "PROCESS.md; redteam/pass-02-2026-09-27.md; redteam/identifier-audit.md; redteam/claim-audit.md; redteam/change-log.md"
  },
  "consensus_validation": {
    "slug": "pku-phenylalanine",
    "completed": true,
    "provider_mode": "Consensus MCP keyword search and record fetch; independent reconciliation against the frozen primary-source ledger and its recorded abstract/full-text access",
    "cutoff": "2026-09-27 (frozen review cutoff)",
    "queries": [
      "phenylalanine neurotoxicity phenylketonuria adults maternal PKU treatment thresholds natural history primary studies",
      "high phenylalanine levels directly affect mood sustained attention adults PKU randomized double blind placebo crossover ten Hoedt 2011 Bickel early diet trial PMID"
    ],
    "raw_paths": [
      "checks/pku-phenylalanine/consensus-search-01.json",
      "checks/pku-phenylalanine/consensus-search-03.json",
      "checks/pku-phenylalanine/consensus-fetch-52d7807e903f558e958a1c93b2eb2eac.json",
      "checks/pku-phenylalanine/consensus-fetch-6dd3f0308a8a50fdab2dbac1cb7f56e6.json"
    ],
    "source_counts_preserved": {
      "evidence_inventory_rows": 27,
      "claims": 35
    },
    "primary_comparisons": [
      {
        "pmid": "13098090",
        "doi": "10.1016/S0140-6736(53)90473-5",
        "review_source_n": 1,
        "source_type": "primary human intervention, single historical case",
        "access_depth": "Full two-page original read from scanned primary-paper copy; bibliographic metadata checked; PubMed has no abstract",
        "result_comparison": "Phe add-back changed neurologic/behavioral state in one case; does not prove developmental prevention/reversal; already present.",
        "already_present": true
      },
      {
        "pmid": "21153445",
        "doi": "10.1007/s10545-010-9253-9",
        "review_source_n": 9,
        "source_type": "primary randomized double-blind crossover adult challenge",
        "access_depth": "Original abstract and bibliographic/status metadata read in Europe PMC; Entrez/web cross-check",
        "result_comparison": "Phe supplementation affected adult mood and sustained attention; acute adult outcome is narrower than untreated childhood ID; already present.",
        "already_present": true
      },
      {
        "pmid": "38569786",
        "doi": "10.1016/j.ajcnut.2023.11.007",
        "review_source_n": 10,
        "source_type": "primary randomized crossover adult challenge",
        "access_depth": "Original abstract and bibliographic/status metadata read in Europe PMC; Entrez/web cross-check",
        "result_comparison": "In early-treated adults the 4-week higher-Phe arm was noninferior for primary working-memory accuracy; does not establish childhood/lifelong safety; already present.",
        "already_present": true
      },
      {
        "pmid": "4140266",
        "doi": "10.1016/S0140-6736(74)91873-X",
        "review_source_n": 2,
        "source_type": "primary observational/natural-history treatment-timing study",
        "access_depth": "Original-paper abstract and bibliographic/status metadata read in indexed records; Entrez/web cross-check",
        "result_comparison": "Early-versus-late treatment history supports the developmental importance of early control, bounded by historical and ascertainment confounding; already present.",
        "already_present": true
      }
    ],
    "score_before": {
      "hsef_level": "Θ",
      "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions",
      "confidence": "High",
      "confidence_rationale": "Historical human developmental evidence, specific exposure challenges, longitudinal replication and controlled/genetically targeted models converge. Confidence describes reproducibility of the causal pattern, not GRADE certainty for every effect size or precision of the Η/Θ boundary. Pass-02 adds maternal-PKU and meta-analytic replication; unchanged band.",
      "rests_on_non_peer_reviewed_work": false,
      "rationale": "SC1 Θ, SC2 Θ and SC3 Θ yield Θ by the preregistered weakest-link rule. Phe accumulation predicts untreated natural history, early-treatment rescue, dose-response on timing and control, and maternal-exposure injury in offspring without PAH deficiency. The rare protected untreated phenotype is unexplained and blocks Ω.",
      "merge_note": "Three independent gradings: A Θ, B Η, R2 (blind) Θ. Pass-01 posted Η; pass-02 raises SC2 and the aggregate to Θ and records B's and pass-01's Η case in full."
    },
    "score_after": {
      "hsef_level": "Θ",
      "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions",
      "confidence": "High",
      "confidence_rationale": "Historical human developmental evidence, specific exposure challenges, longitudinal replication and controlled/genetically targeted models converge. Confidence describes reproducibility of the causal pattern, not GRADE certainty for every effect size or precision of the Η/Θ boundary. Pass-02 adds maternal-PKU and meta-analytic replication; unchanged band.",
      "rests_on_non_peer_reviewed_work": false,
      "rationale": "SC1 Θ, SC2 Θ and SC3 Θ yield Θ by the preregistered weakest-link rule. Phe accumulation predicts untreated natural history, early-treatment rescue, dose-response on timing and control, and maternal-exposure injury in offspring without PAH deficiency. The rare protected untreated phenotype is unexplained and blocks Ω.",
      "merge_note": "Three independent gradings: A Θ, B Η, R2 (blind) Θ. Pass-01 posted Η; pass-02 raises SC2 and the aggregate to Θ and records B's and pass-01's Η case in full."
    },
    "grade_changed": false,
    "conclusion": "The checked adult challenge papers do not overturn the developmental PKU claim and do not resolve its rare untreated exception. Short-term adult sensitivity is not equivalent to childhood developmental injury. Consensus discovery changes neither grade nor original inventory.",
    "addendum_path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\consensus-addendum.md",
    "independent_blinded_audit": false,
    "additional_original_source_receipts": [
      "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\primary-source-verification.json",
      "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\primary-source-verification.md"
    ],
    "primary_comparison_count": 4,
    "status": "completed_retrospective_original_source_reconciliation",
    "raw_receipts": [
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\consensus-search-01.json",
        "sha256": "9318faa8137407e9fc26f3b8e0aee6da2cc9ca5f265bc6c24f599d21d1ee327a"
      },
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\consensus-search-03.json",
        "sha256": "304c0edcc7cf6ad98c381eac9e235ae8e60097ac20a30b3795a8615cf3e31293"
      },
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\consensus-fetch-52d7807e903f558e958a1c93b2eb2eac.json",
        "sha256": "f9902121caa42ffe0cabe0b6579c3fb2d133088d45588c250221ab521d61d32a"
      },
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\consensus-fetch-6dd3f0308a8a50fdab2dbac1cb7f56e6.json",
        "sha256": "e0b952881740c8f6eb5ab698abddcb7b47b635907464d02435a074d468773665"
      },
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\primary-source-verification.json",
        "sha256": "780132247a0511e97247fa21d64ae1fc0cdb359e18ecd054b5e1ce3ba0cfb8d8"
      },
      {
        "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\primary-source-verification.md",
        "sha256": "5d5a0fc1a4db24878a6fdda9bf9948a94635fcc95932f5564a305174cf77f132"
      }
    ],
    "manifest_source": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\pku-phenylalanine\\final-structured-consensus-validation.json",
    "literature_cutoff_preserved": true
  }
}